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The influence of ethanol (EtOH) on multiple dendritic cell (DC) subsets, either in steady state or 
following mobilization in vivo, has not been characterized.  Herein, the generation of mouse 
bone marrow (BM)-derived DC in fms-like tyrosine kinase 3 ligand was inhibited by 
physiologically-relevant concentrations of EtOH, with selective suppression of plasmacytoid 
(p)DC.  EtOH reduced surface expression of costimulatory (CD40, CD80, CD86) but not 
coinhibitory CD274 (B7-H1) molecules on resting or CpG-stimulated DC subsets.  IL-12p70 
production by activated DC was impaired.  Consistent with these findings, EtOH-exposed 
(E)BMDC exhibited reduced capacity to induce naïve allogeneic T cell proliferation and 
impaired ability to prime T cells in vivo.  Further, T cells from animals primed with EBMDC 
produced elevated levels of IL-10 following ex vivo challenge with donor alloantigen.  DC 
subsets freshly-isolated from EtOH-fed mice were also examined.  Liver DC, inherently 
immature and resistant to maturation, exhibited little change in low surface cosignaling molecule 
expression, whereas splenic DC showed reduced expression of cosignaling molecules in 
response to CpG stimulation. These splenic DC elicited reduced naïve allogeneic T cell 
proliferation in vitro, while the stimulatory capacity of resting but not CpG-activated liver DC 
was reduced by EtOH administration.  In vivo, hepatic EDC elicited increased capacity to prime 
T cells compared to control hepatic DC.  Conversely, splenic EDC exhibited impaired ability to 
prime T cells in vivo.  This differential capacity of hepatic versus splenic EDC compared to 
control DC to prime T cells in vivo is likely due to several factors including differential 
phenotype and migratory capacity.  In fact, liver EDC migrate in greater numbers to secondary 
lymphoid tissue compared to control liver DC.  Thus, EtOH impairs cytokine-driven 
differentiation and function of mDC and pDC in vitro.  Hepatic DC from chronic EtOH-fed mice 
are differentially affected compared to splenic DC.  Splenic DC exhibit impaired functional 
maturation following CpG stimulation while hepatic DC exhibit altered migration to secondary 
lymphoid tissue.  In addition to examining the effects of chronic EtOH exposure on DC, we have 
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evaluated cell-mediated and humoral responses in EtOH-fed mice.  In total, these results indicate 
potential mechanisms by which alcohol consumption is associated with immunosuppression. 
 v 
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1.0  INTRODUCTION1 
Alcoholism is a leading cause of morbidity and mortality.  Epidemiological studies have shown 
that chronic EtOH abuse increases susceptibility to bacterial pneumonia and tuberculosis and 
exacerbation of the pathologic course of hepatitis C virus (HCV) infection.  While some of the 
effects of alcohol on cells of the immune system are known (i.e. reduced number and altered 
subsets of lymphocytes as well as impaired cell-mediated immunity), the mechanisms by which 
EtOH exerts these immunosuppressive effects are still unknown.  Based on the known immune 
compromised status of alcoholics and previous findings of impaired leukocyte function, we 
hypothesize that chronic ethanol exposure impairs DC subset development and function, 
perhaps differentially, and that this impairment results in the compromised ability of 
alcoholics to mount appropriate responses to TLR ligation.  
There is a clear need to better understand the mechanisms underlying the EtOH-induced 
immune compromised status of alcohol abusers.  Further, a murine model of chronic EtOH 
consumption should be characterized and evaluated for its potential in evaluating immune 
function and disease states in relation to human (immune) impairments.  In Chapter 2, we 
present our findings regarding the impact of prolonged EtOH exposure on mouse BM-derived 
mDC and pDC using mainly in vitro approaches.  In Chapter 3, we expand our observations to 
DC freshly-isolated from the liver and spleen of EtOH-fed (compared to control) mice.  Here, 
along with ex vivo analyses, we employ adoptive transfer of DC to naïve animals to evaluate 
their function (ability to migrate and prime T cells).  Finally, in Chapter 4, we evaluate the 
effects of chronic EtOH consumption on cell-mediated and humoral immune responses to a 
model Ag.    
                                                 
1 Text excerpted from (1, 2),  from (1), and Table 2 from (1). Figure 3
1 
1.1 DENDRITIC CELLS 
Although rare, bone marrow (BM)-derived dendritic cells (DC) are the most highly-specialized 
antigen (Ag)-presenting cells (APC), with ability both to instigate and regulate immune 
reactivity, and capable of activating T lymphocytes at both low concentrations of Ag and 
APC/lymphocyte ratios.  In addition, DC are well-equipped to migrate from peripheral tissue 
sites, such as the liver, to regional (secondary) lymphoid organs, where they present Ag to T 
cells.  In the normal steady state, these events may be important in the maintenance of self 
tolerance.  It is now recognized that the microenvironment in which APC develop or are 
activated influences their function and their effects on T cell populations.  Furthermore, different 
DC subsets have been identified that exhibit distinct functional capabilities.   
Once immature DC have taken up residency in peripheral tissue from the blood, they 
constantly survey their microenvironment through vesicular exchange with other resident cells 
and the uptake of apoptotic cells and soluble material.  Even in the absence of stimulation via 
pathogen products, other Toll-like receptor (TLR) ligands or alloAg, DC constantly migrate from 
peripheral tissue sites via the lymphatics to draining lymphoid tissue.  These DC may express 
self-peptide in the context of self major histocompatibility complex (MHC) gene products.  
While in the normal steady state they are generally immature, expressing low levels of surface 
MHC and costimulatory molecules, they may also be considered ‘semi-mature’ if they express 
moderate levels of T cell costimulatory molecules (in particular, CD80 and CD86).  It is thought 
that, once these DC expressing self-peptide reach secondary lymphoid tissue, they play a role in 
maintenance of peripheral T cell tolerance via one or more mechanisms that include deletion of 
Ag-specific T cells via apoptosis, induction of T cell anergy resulting from Ag presentation 
without appropriate costimulation, and the generation of T regulatory cells (Treg) that actively 
suppress T cell responses. 
When DC are activated or matured by Ag and/or stimuli [i.e. pathogen-associated 
molecular patterns (PAMPs) or cytokines], they upregulate their Ag processing and presenting 
ability, co-regulatory molecule expression, and cytokine production, while down-regulating their 
Ag capture (3-6).  These mature DC induce adaptive immune responses through presentation of 
Ag peptides on MHC class I and class II molecules for presentation to CD8+and CD4 +
 
 T cells, 
respectively (5).  DC can further induce potent T cell immune responses by upregulation of 
2 
costimulatory molecules, such as CD40, CD80, and CD86, while further influencing T cells 
through the secretion of cytokines (3, 4, 6).   
Thus, DC can provide (potently) the three signals that naïve T cells require to become 
activated:  (1) T cell receptor (TCR)/MHC ligation; (2) CD28/CD80/CD86 costimulation; and 
(3) secretion of T helper cell (Th)-inducing cytokines by DC, such as interleukin (IL)-12 and IL-
18.  In the absence of signal one, naïve and memory T cells fail to become activated.  In the 
absence of signal two, naïve T cells can become anergic or apoptotic.  Signal three is important 
in determining the polarization of the T cell response, such as skewing towards Th1/Th2 or 
generating Treg.   Memory T cells do not need all three signals and therefore can also be activated 
by non-DC APC, such as macrophages, B cells, and in special cases, some types of endothelial 
cells (EC) (7-12). 
1.1.1 DC Subsets 
Various DC subsets have been identified in both human and animal models, each with 
differential roles in the induction of Ag-specific T cell immune responses (13, 14).  The DC 
subsets that have currently been identified are the myeloid (m) and plasmacytoid (p) subsets.  
Another commonly studied subset in the mouse is the ‘lymphoid-related’ DC subset, however, 
no human counterpart has yet been identified.  Murine DC can be identified by expression of 
CD11c, the integrin-αx chain.   
1.1.1.1 Myeloid and lymphoid-related DC 
mDC (CD11c+CD8α-CD11b+) and ‘lymphoid-related’ DC (CD11c+CD8α+CD11b-/lo) are 
distinguished by their reciprocal expression of CD8α (homodimer) and CD11b and were thought 
initially to be of distinct lineage and to exhibit distinct functions (14, 15).  Recent evidence has 
shown that these subsets derive from a common precursor and that rigid lineage affiliations 
between subsets may not exist (14, 15).  In addition to differences in phenotype, mDC and 
lymphoid-related DC have been shown to differ in tissue localization, and, potentially, in 
function. 
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In addition to the high surface expression of CD11b and the absence of CD8α, mDC are 
also characterized by their low to lack of expression of CD205 (DEC-205).  In contrast, 
‘lymphoid-related’ (CD8α+) DC express high levels of CD205.  However, when mDC are 
cultured in vitro or are stimulated with lipopolysaccharide [LPS; Toll-like receptor (TLR)4 
ligand], they have been shown to upregulate CD205 (13).  Thus, the surface expression of 
various markers, such as CD205, is not unique to one subset and may be more ubiquitous in 
expression.    
mDC and ‘lymphoid-related’ DC differ in terms of their localization in secondary 
lymphoid tissues.  Whereas mDC reside in the marginal zones of lymphoid tissue, ‘lymphoid-
related’ DC can be found in the T cell-rich areas of periarteriolar lymphatic sheaths (PALS) (13).  
However, mDC have been shown to localize in the PALS when stimulated by the 
proinflammatory TLR4 ligand LPS (13). 
Functionally, early experiments with mDC suggested that they were a Th1-inducing DC 
subset (16, 17), but quickly thereafter, mDC were shown to induce Th2 cells as well (18).  The 
‘lymphoid-related’ subset has been suggested to be a more “suppressive” DC subset, reportedly 
by inducing CD4+ T cell apoptosis (19) or suppressing CD8+ T cell proliferation via suppression 
of IL-2 production (20).  Further, our lab has shown that DC administration of immature or 
mature CD8α+ DC significantly prolongs mouse heart allograft survival, whereas immature mDC 
could only delay graft rejection; further, administration of mature mDC accelerated the rejection 
process (21).  More recently, it was shown that populations of mDC containing 3% CD8α+
 
DC 
were impaired in their ability to induce an immune response against a tumorigenic self-peptide 
due to CD8α+
 
DC secretion of indoleamine 2,3-dioxygenase (IDO), an enzyme of the tryptophan 
catabolizing pathway which has been shown to inhibit T cell proliferation (22).  This suppressive 
effect of CD8α+
 
DC on mDC immunogenicity was abrogated by the addition of IL-12 to cultures 
(22).  The effects of additional IL-12 is blocked by further adding IFNγ to these cultures (regain 
CD8α+ DC-mediated suppression) (23). 
In spite of differences in the phenotype, function, and localization of mDC and 
‘lymphoid-related’ DC, it has been suggested that CD8α is a marker of activation and not of 
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expression after uptake of intravenous (i.v.)-administered allogeneic 
apoptotic bodies.  Langerhans cells (LC), DC which reside in the skin epidermis, are also 
interesting in regard to their expression of CD8α, CD11b, and CD205.  LC express CD205 and 
upregulate CD8α expression after CD40 ligation and subsequent migration to lymph nodes (26).  
Thus, the true role or function of CD8α and associated differences between myeloid and 
‘lymphoid-related’ subsets has yet to be clearly defined.    
1.1.1.2 Plasmacytoid DC 
pDC were known to exist for over forty years as natural type-1 interferon (IFN)-
producing cells, but their hematopoietic origin was not discovered until recently.  These cells 
were recently identified in humans and mice as a subset of DC (27).  DC isolated from humans 
and mice (Figure 1) have similar morphology and function (28-30), showing typical 
plasmacytoid appearance, with a smooth cell surface, a prominent, lobular nucleus, and clear 
perinuclear area.  Both human and murine pDC produce large amounts of type I IFNs in 
response to certain types of viruses and microbial products (Reviewed in 31).  However, there 
exist differences in their phenotypical markers.  Human pDC express CD123 (IL-3 receptor α 
chain) but are CD11c negative or low, while murine pDC express CD45R (B220) and CD11c.  
Recently, a subset of pDC expressing CD19 has been reported with potential potent tolerogenic 
capability (32, 33). 
In spite of the fact that IFNα is a Th1 cytokine (generally considered 
immunostimulatory), evidence supports pDC as a tolerogenic DC subset (34-37).  This theory is 
supported by studies that show the induction of Treg  (27) and production of IDO by pDC (38, 32, 
33).  However, pDC have also been shown to induce adaptive immunity, with the ability to 
prime Ag-specific naïve CD8+ T cells and potentiating skewing of Th1 cells (39).  Thus, pDC are 
being studied for their potential as tools for induction of transplant tolerance (40, 41) and 
autoimmune regulation (39), as well as initiating and amplifying T cell activation (39).   
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Figure 1.  Giemsa stain (x1000) of murine hepatic plasmacytoid (p)DC purified by cell sorting as described in 
3.2.8. 
1.1.2 Origin and Development of DC 
As briefly alluded to above, it was previously believed that murine mDC and ‘lymphoid-related’ 
DC arose from common myeloid and lymphoid hematopoietic precursors; thus, the resultant 
subset monikers (14, 15).  However, subsequent studies using mutant mice (either the c-kit-γc- or 
conditional Notch-1 knockout), which cannot form T cells, showed that ‘lymphoid-related’ DC 
were still present, and disproved the theory that ‘lymphoid-related’ DC were derived from 
common lymphoid precursors (14, 15).  Further, studies have shown that both mDC and 
‘lymphoid-related’
 
DC can be generated from either progenitor cell type (14, 15).  Human pDC 
were also originally believed to derive from a lymphoid progenitor due to lack of myeloid 
markers as well as distinct growth requirements (39).  However, mouse studies have challenged 
this hypothesis as a common CD11c+ precursor, as well as common lymphoid and myeloid 
progenitors, can generate both pDC and mDC (15).   A DC-specific precursor that only gives rise 
to DC has yet to be identified.   
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1.1.3 DC Activation by TLR 
TLR are highly conserved major pattern recognition receptors for a variety of pathogenic 
structures, termed PAMPs.  At present, eleven different TLR have been identified that recognize 
a variety of self, microbial, or synthetic structures, ranging from lipoproteins to double-stranded 
(ds)RNA to endogenous proteins, such as heat shock proteins (HSP) (42) (Table 1).  TLR9 binds 
bacterial unmethylated deocycytidylate-phosphate-deoxyguanylate oligodeoxynucleotides (CpG) 
motifs (43, 44) while TLR3 recognizes dsRNA synthesized by viruses (45).  Some TLR, such as 
TLR7 and -8 not only bind viral ssRNA, but they also recognize synthetic anti-viral compounds, 
such as imidazoquinoline compounds (46) or the guanosine analog Loxoribine (47). 
Both leukocyte and DC subsets express different patterns of TLR that differentially affect 
their ability to respond to the same stimuli.  Further, counterpart DC subsets from humans and 
mice show differential expression of TLR (Table 1) (42, 48).  In the mouse, expression of TLR 
on DC subsets is more ubiquitous than on human DC subsets (Table 1).  Reverse transcriptase 
polymerase chain reaction (RT-PCR) analysis of highly-purified, flow-sorted, murine splenic and 
hepatic pDC performed in our laboratory shows a different and distinct pattern of TLR 
expression, with most of TLR1-10 variably expressed (De Creus, A et al., unpublished 
observations; data not shown).  Activation of both human and murine pDC via TLR7 and TLR9 
leads to high levels of IFN-α production, followed by their development into mature DC (31).  
The production of IL-12 by human pDC is debated, but IL-12p70 is known to be produced by 
mouse pDC (31).   
TLR are known to signal through two primary pathways, the MyD88 (myeloid 
differentiation primary-response protein 88) (MyD88-dependent) and TRIF (Toll/Interleukin-1 
receptor-domain containing adaptor protein inducing IFN-β) (MyD88-independent) pathways  
(Figure 2) (42).  TLR3 and TLR4 have been shown to signal through the both the MyD88-
dependent and -independent pathways, while other pathways appear to rely on the adaptor 
protein MyD88 for TLR signaling (Figure 2) (42).  Further, signaling via all known TLR tested 
results in an increase in costimulatory molecule expression by DC, which is dependent on the 
nuclear translocation of nuclear factor-kappa B (NF-κB) (42).   
Stimulation of DC via TLR is believed to play a crucial role in regulating innate and 
adaptive immune responses.  Recent studies have indicated a role for TLR (MyD88-dependent 
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pathways and TLR7) signaling favoring the differentiation of Th1 cells and inhibiting Th2 cells 
by inducing IL-12 production by APC (49-51).  Other studies show that the type of Th response 
may be dependent upon which TLR is stimulated (52) or upon Ag dose (53).  More recently, the 
effects of simultaneously triggering DC through multiple TLR have been investigated (54).  
Napolitani et al. (54) found that TLR3 and TLR4 acted synergistically with TLR7, TLR8, and 
TLR9, enhancing and sustaining a Th1-polarizing DC.   
One of the most extensively studied TLR is TLR9.  In humans, TLR9 expression is 
restricted to pDC while in mice, TLR9 expression on various DC subsets is ubiquitous (Table 1) 
(55, 56).  Accordingly, pDC are the primary cells that respond to CpG in the human, secreting 
large amounts of type 1 IFN.  In murine systems, however, due to the ubiquitous expression of 
TLR9, CpGs act directly on pDC as well as other DC subsets (40, 57).  Furthermore, and 
highlighting the inherent differences between murine and human systems, TLR9 in each system 
preferentially responds to different CpG motifs (58, 59).  Thus, although there are differences 
between TLR expression and possibly function between the human and murine systems, much 
information can be learned about the role of DC in immune response and more importantly, 
about manipulation or directing the immune response through DC, by studying TLR signaling in 
the murine system to examine potential crossover effects or perhaps even therapeutic use in 
humans 
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Figure 2.  (A) Cell-surface and (B) intracellular TLR signaling pathways. 
(A) TLR-1, -2, -4, -5, -6, and -11 are located on the cell surface and, when activated by appropriate ligands, signal 
through MyD88-dependent or –independent pathways.  TLR-1 and -6 cooperate with TLR2.  (B)  TLR-3, -7, and -9 
are localized in intracellular acidic compartments (endosome).  TLR3 mediates dsRNA-induced responses via 
TRAM/TRIF dependent signals while TLR-7 and -9 utilizes the MyD88 signaling pathway.  TLR activate via 
different cell signaling pathways and, ultimately, upregulate the transcription of different inducible genes (i.e. NF-
κB, AP-1, IFNs).  Abbreviations:  AP-1, activating protein-1; IRF, interferon regulatory factor; IKK, IκB kinase; 
IRAK, interleukin-1 receptor-associated kinase; MAPK, mitogen-activated protein kinase; MyD88, myeloid 
differentiation primary response gene; NF-κB, nuclear factor kappa B; TBK-1, TANK-binding kinase-1; TIRAP, 
Toll/IL-1R receptor domain-containing adaptor protein; TRAM, TRIF-related adaptor molecule; TRIF, Toll/IL-1 
receptor domain-containing adaptor inducing IFN-β.  Modified from (63, 64). 
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1.1.4 In vivo-derived and in vitro-generated DC 
1.1.4.1 Freshly-Isolated DC (Immature DC or DC Progenitors) 
CD11c+ DC of phenotypically distinct subsets have been described and isolated from 
various murine tissues (65-68, 30, 37, 69-71).  These include the classic myeloid DC (CD11b+ 
CD8α-), ‘lymphoid-related’ DC (CD11b-CD8α+), and more recently, plasmacytoid DC (pDC; 
B220+).  When CD11c+ DC are freshly-isolated from normal lymphoid or non-myphoid tissues 
(such as spleen or liver), they are immature in surface phenotype, as characterized by low CD40, 
CD80, CD86, and MHC II expression.  Such immature DC of donor origin, when infused prior 
to transplantation, prolong organ (72) or pancreatic islet (73) allograft survival, without use of 
immunosuppressive therapy.  The mechanisms by which these freshly-isolated DC promote 
tolerance when administered in experimental transplant models have not been fully elucidated.  
Hypotheses to explain this phenomenon include induction of T cell anergy/apoptosis by 
allogeneic DC expressing low or no levels of classical costimulatory molecules (signal 2), or 
induction of Treg capable of suppressing alloreactive T cell responses. 
Due to the rarity of freshly-isolated tissue-resident DC, mice are typically pre-treated 
with endogenous hematopoietic growth factors such as granulocyte macrophage colony 
stimulating factor (GM-CSF) or fms-like tyrosine kinase 3 ligand (Flt3L).  Many investigators 
administer Flt3L intraperitoneally (i.p.) into mice for 10 days before sacrifice, as it expands all 
three DC subsets, whereas GM-CSF selectively expands the CD8α-
 
DC population (74, 75).  
Flt3L dramatically increases DC in the BM, gut-associated lymphatic tissue (GALT), liver, 
spleen, LN, lung, peritoneal cavity, thymus, and (peripheral) blood, in addition to stem cells and 
various other leukocyte populations (76).  DC from Flt3L-treated mice are otherwise reportedly 
identical to DC from non-growth factor treated mice.   
Freshly-isolated DC may also be innately different in their function depending upon their 
tissue of origin.  For example, the liver microenvironment is high in the immunosuppressive 
cytokines IL-10 and TGF-β1, that may have direct inhibitory effects on DC development, 
maturation, and function (77).  Freshly-isolated DC from the respiratory tract, intestinal Peyer’s 
patches, and liver have been found to be poor allostimulators of T cells in mixed leukocyte 
reactions (MLR) (78).  Accordingly, these DC are poor synthesizers of bioactive IL-12p70, but 
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exhibit high levels IL-10 mRNA expression or protein (78).  DC isolated from a specific 
location, such as the liver, may have the potential to promote tolerance because of an inherent 
tolerogenic capacity, such as in endotoxin tolerance (in response to gut-derived LPS) mediated 
via TLR4 in liver DC (79).    
In addition to potential differences in cytokine production by various tissue-resident DC, 
these APC may also be the source of potential immunoregulatory proteins.  Indeed, there may be 
preferential or exclusive production of specific immunoregulatory proteins by certain DC 
subsets.  For example, much recent interest has focused on indoleamine-2,3-dioxygenase (IDO) 
which has been shown to suppress T cell proliferation by catabolizing tryptophan upon which T 
cell replication is dependent.  Several groups have examined the role of IDO in DC function.  
Mellor et al. (80) showed recently that, in mice treated with the B7-CD28 pathway inhibitor 
CTLA4Ig, splenic DC subsets, including CD8α+ DC, pDC, and bitypic natural killer/DC 
regulatory cells (81) (NK DC; DX5+CD11c+CD8α+), upregulated IDO production.  Our 
laboratory has preliminary data that support the hypothesis that IDO production may be one 
contributing factor to tolerance induction by freshly-isolated pDC.  Freshly-isolated murine 
splenic pDC strongly express mRNA for IDO, in contrast to myeloid and CD8α+ DC.  Similar to 
other freshly-isolated DC subsets, freshly-isolated (splenic) pDC of donor origin can 
significantly prolong murine cardiac allograft survival (82).   
While it is known that administration of freshly-isolated DC can promote tolerance in the 
context of experimental transplantation, the specific mechanisms by which different DC subsets 
achieve this effect are not yet understood.  Methods to enhance the capacity of freshly-isolated 
DC to induce tolerance are under study.  In particular, tissue-specific DC are being studied for 
their differences in maturation and function and thus their ability to promote tolerance.  Addition 
of other therapeutic agents, such as immunosuppressive drugs, other agents that are known to 
subvert DC maturation, and those that block costimulation, in concert with freshly-isolated or in 
vitro-propagated DC is under investigation.   
1.1.4.2 DC generated under specific culture conditions 
While freshly-isolated DC have been shown to promote tolerance in experimental 
models, practical issues concerning their clinical use have arisen.  Many studies have used BM-
derived DC or DC from other tissues, especially spleen or thymus, which would not normally be 
12 
available for human use.   Furthermore, the timing of the isolation or propagation of these DC 
must be considered in relation to when (e.g. in relation to cadaveric organ transplantation or 
development of autoimmune disease) the DC would be needed for therapeutic administration.  A 
growing area of interest is in culturing DC from BM progenitors or blood-borne precursors under 
specific conditions which render the DC tolerogenic.   
mDC are commonly generated in bulk from BM progenitors by the addition of 
granulocyte-macrophage colony-stimulating factor (GM-CSF, with or without IL-4) to the 
culture.  mDC generated in this manner are a heterogenous population of immature and semi-
mature APC.  In the non-obese diabetic (NOD) mouse model of type-1 diabetes, it has been 
shown that administration of syngeneic BMDC generated with GM-CSF and IL-4 to pre-diabetic 
mice prevents the onset of autoimmune disease (83).  T cells from DC-treated mice were found 
to have Th2-like properties, such as the production of high levels of Th2 cytokines.   
By adding other cytokines or stimuli to DC cultures, the phenotype and function of these 
cells can be altered.  Lutz et al. (84) reported that murine DC propagated from BM progenitors in 
GM-CSF and treated concurrently with a high dose of lipopolysaccharide (LPS) are immature 
and induce alloAg-specific CD4+ T cell anergy in vitro.  By altering the culture conditions, Sato 
et al. (85) have generated an ‘alternatively-activated’ regulatory DC population capable of 
inducing tolerance in allogeneic BM transplantation.  These DC, termed regulatory DC (rDC), 
are generated with GM-CSF, IL-10 and transforming growth factor (TGF)-β and stimulated with 
high dose LPS near the end of culture.  These rDC express very little CD80 or CD86 but high 
levels of MHC II.  Further, these rDC are very poor stimulators in allogeneic MLR as compared 
to Vitamin D3-conditioned DC.  In an elegant study using a mouse model of acute graft-versus-
host-disease (GVHD), Sato et al. (86) found that treatment of recipient mice with host-matched 
rDC 2 days after transplantation prevented acute lethal GVHD which was Ag-specific and 
complete.  In studying the mechanism by which the rDC exerted their action, CD4+ T cells from 
rDC-treated recipients were hyporesponsive to stimulation with host-type mature DC, while 
CD8+ T cells had reduced lytic activity against host-matched target cells.  Furthermore, the 
authors were able to characterize Ag-specific IL-10-producing Treg (CD4
+) in protected, rDC-
treated mice.  More recently, Fujita et al. (87) have shown that LPS-induced lethal endotoxemia 
(sepsis) was prevented with rDC treatment, either as pretreatment or when treatment was given 
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after onset of disease (2 h post).  Further, IL-10-production by these rDC was found to be 
significantly involved in their inhibitory effects (87). 
pDC can also be generated in vitro from murine BM cells or human CD34+ stem cells in 
response to the hematopoietic growth factor fms-like tyrosine 3 kinase ligand (Flt3L) and these 
cells are an accepted model for the study of pDC activation and function (Reviewed in 31).  It 
has been shown that these cultured pDC exhibit the morphology, known pDC phenotypical 
markers, and the ability to produce IFN-α as pDC isolated ex vivo.  As discussed above, in vivo-
mobilized freshly-isolated donor splenic pDC can prolong graft acceptance in murine transplant 
models.  Recent evidence suggests that cultured BM-derived pDC, which are also immature in 
phenotype, can similarly prolong graft survival (88).   
It has been shown that BM-derived DC, which can be cultured in large quantities, can be 
modified by adjusting the culture conditions.  Tolerogenic or rDC have been generated that, in 
experimental animal models, can induce tolerant states.  For example, Fugier-Vivier et al. have 
shown that BMpDC can be used to enchance allogeneic BM cell engraftment and also promote 
skin graft tolerance (89).  Thus, there is considerable potential for the use of this technology in 
developing DC-based therapy for tolerance induction, e.g. in the context of living-related organ 
transplantation, which would provide the necessary time for culture and administration of these 
cells to recipients prior to surgery. 
1.1.5 DC Migration 
Trafficking of DC is an important component in their ability to regulate immune responses.  If 
there is an inhibition or dysfunction in the migration of DC to either the site of inflammation or 
subsequently to secondary lymphoid tissues, then DC activation or T cell activation will be 
impaired.  Both adhesion molecules as well as chemokine production/chemokine receptors are 
important in the migration of DC and will be discussed below.  It is also important to note the 
ubiquitous nature of the expression of adhesion molecules; they are not always limited to sole 
expression on leukocytes or EC. 
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1.1.5.1 Adhesion molecules and DC migration 
The trafficking of DC in vivo requires interactions between DC and endothelial cells 
(EC).  There are three important stages in the migration of DC – rolling, adhesion/tethering, and 
transendothelial migration, all which require different classes and families of intercellular 
adhesion molecules.  In both steady-state and inflammatory situations, immature DC exit the 
bloodstream, via interactions between selectins and integrins on DC with carbohydrate structures 
and Ig superfamily members on EC for rolling and tethering, respectively, followed by 
transendothelial extravasation into peripheral tissue.  Upon entrance into peripheral tissue, 
immature DC survey the environment, uptake Ag, begin to mature, and modify their chemokine 
receptor (CR) expression (90).  These maturing DC concurrently downregulate CR for 
inflammatory chemokines (i.e. CCR5) while upregulating CR for lymphoid chemokines (i.e. 
CCR7), initiating recruitment of the DC to secondary lymphoid tissues (90).   
The initial two steps of migration of DC, leukocyte rolling and tethering, have been 
studied comprehensively in the human as well as in mouse models.  Rolling, the initial step in 
DC migration, involves weak binding of DC to EC, allowing the DC to survey their environment 
for chemokine gradients, as well as the expression of adhesion/tethering molecules.  This initial 
step in trafficking requires the expression of selectins and glycosylated carbohydrate structures 
on DC or EC, such as CD62E/E-selectin (on APC and EC), CD62L/L-selectin (primarily on 
APC), CD62P/P-selectin (on EC), Sialyl Lewis molecules (SLe, on APC and EC), MAdCAM-1 
and GlyCAM-1 [on lymphoid high endothelial venules (HEV)], and CD24 and CD162/P-selectin 
glycoprotein ligand-1 (on APC) (91, 92). 
Once DC have started to roll on EC, stronger cell-to-cell adhesion interactions are 
mediated by the integrin and IgG superfamily molecules.  CD54/intercellular adhesion molecule 
(ICAM)-1 is important in cell-cell adhesion and is ubiquitously expressed on EC as well as 
various leukocytes (91-93).  Its ligands, CD11a/CD18 [lymphocyte function associated Ag 
(LFA)-1] and CD11b/CD18 (Mac-1) bind multiple molecules in addition to CD54, but are 
limited to expression on leukocytes (91).  CD11a/CD18 is especially important in mediating cell-
cell interactions and subsequent functions with blockade of CD11a/CD18 impairing not only 
adhesion to EC, but also blocking T cell responses (91).  CD102/ICAM-2 and CD50/ICAM-3 are 
expressed on both EC and leukocytes, although their expression is variable, and are important in 
mediating adhesion of leukocytes to EC through interaction with ligand CD11a/CD18 (91).  
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CD106/vascular cell adhesion molecule (VCAM)-1 is located primarily on EC, especially upon 
activation (93), but is also expressed on multiple non-EC populations, including follicular DC 
(94, 95).  Its ligand, CD49d/VLA-4, is also broadly expressed on leukocytes (91). 
Transendothelial migration has recently become the subject of further study.  It is well 
accepted that leukocytes extravasate through paracellular routes, by undergoing diapedesis 
between EC, with various adhesion molecules, i.e. CD11a/CD18, CD11b/CD18, and CD54, 
essentially involved (96).  However, most transendothelial migration studies have not 
specifically studied DC extravasation.  In paracellular migration, it is believed that leukocytes 
encounter homophilic interactions of EC junctional molecules, such CD31/platelet endothelial 
cell adhesion molecule (PECAM)-1, members of the junctional adhesion molecules (JAM) 
family, and possibly CD99 which, in conjunction with redistribution of vascular endothelial 
cadherin out of the junction and to the EC cell surface, guide leukocyte migration through the 
intercellular cleft (97, 98, 96).  Another possible mechanism for leukocyte extravasation is via 
the transcellular pathway.  Studies investigating leukocyte movement across the blood brain 
barrier have shown a transcellular pathway of leukocyte migration through EC, while leaving the 
EC junctions intact (96).  Subsequent studies confirm and further characterize the mechanism of 
this pathway (99).  If these findings hold true, it will be necessary to examine whether this 
phenomenon is limited to leukocyte migration across the blood-brain barrier and EC lines (i.e. 
human umbilical vein endothelial cells) or if it represents a more generalized mechanism.  
Further, it will important to know if this pathway is limited to lymphocytes, as suggested by 
Niemenen et al. (100).  
Once DC in the periphery have taken up Ag and begun to mature, they must then undergo 
reverse transmigration through EC into lymphatic vessels, a process which reportedly requires 
CD29 (β1-integrin), CD49d/VLA-4, CD49e/VLA-5 (101), tissue factor and multidrug resistance 
protein 1 (102-104).  This process is likely aided in part by CD54 and tissue factor (member of 
the coagulation cascade) (105, 102), as well as the chemokine gradient of CCL21/secondary 
lymphoid tissue chemokine (SLC) (106). 
Overall, at present, few reports have specifically identified or considered which adhesion 
molecules may be most important in directing DC migration and extravasation.  While most of 
these studies have been limited to human DC that have differed in the state of maturation and 
origin (101, 107), our group published the first report examining adhesion molecules involved in 
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the transendothelial migration of murine DC subsets (108).  Elucidation of which adhesion 
molecules are most important in DC migration would be informative for targeting and 
optimization of therapies, such as immunotherapy (using DC) or receptor/ligand blockade. 
1.1.5.2 Chemokines and DC migration 
Chemokines are small, secreted chemoattractant cytokines that are important in 
inflammatory responses of the host (109, 110).  They have the ability to modulate the migration 
(chemotaxis) of leukocytes, upregulate the expression of adhesion molecules, thus promoting 
diapedesis and infiltration of cells to sites of inflammation (109, 110), as well as roles in 
hematopoiesis, organogenesis, tumor metastases, and angiostasis/angiogenesis (111, 112).   
There are four families of chemokines, C, CC, CXC, and CX3C, named according to the position 
and separation of the first two amino-terminal cysteine residues of a four-cysteine motif (113).  
CR are seven-pass-transmembrane G protein-coupled receptors which are differentially 
expressed on cell subsets (114, 90, 115, 116).   
Chemokines are principal in directing DC migration during an immune response.   
Immature DC express inflammatory CR (113) in anticipation of receiving appropriate 
signaling/ligation by inflammatory chemokines early in an inflammatory response.  Immature 
DC express variable levels of common inflammatory CR such as CCR1-6 with variable function, 
especially when comparing BMDC with splenic DC (117-119).  These receptors bind the classic 
chemokines released by inflamed tissues, CCL3/macrophage inflammatory protein (MIP)-1α, 
CCL4/MIP-1β, and CCL5/Regulated on Activation Normal T cell Expressed and Secreted 
(RANTES) (116).  Recently, Yoneyama et al. (120) have also shown that CXCR3 is important in 
the recruitment of pre-pDC to secondary lymphoid  tissues.  As DC mature, upregulating MHC 
II and costimulatory molecules, DC begin to downregulate their inflammatory receptors while 
upregulating CCR7 and CXCR4 (121, 122).  Thus, semi-mature and mature DC migrate to 
lymphatic vessels, following the CCL21 gradient (115, 123), and, once the DC has departed the 
lymphatic vessels, are directed to T cell areas of the secondary lymphoid tissue by CCL19/MIP-
3β (124, 125) or to B cell areas by CXCL13/B lymphocyte chemoattractant (BLC) (126, 127). 
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1.2 HEPATIC DC 
The unique architecture of the liver allows T cells to interact with resident liver APC, making 
these latter cells, particularly the uniquely well-equipped DC, ideal candidates for directing 
immune responses towards immunity or tolerance.  We speculate that within the liver 
microenvironment, production of anti-inflammatory cytokines and other molecules including 
growth factors, such as IL-10, TGF-β, prostaglandin (PG)E2 and GM-CSF results in the 
modulation of APC differentiation, trafficking and function in both health and disease.  Much 
has recently been discussed about the potential of DC to regulate immune responses and to 
promote tolerance induction.  The aforementioned soluble factors may each play a role in 
‘fashioning’ intra-hepatic tolerogenic DC and other APC. 
In normal liver, hepatic DC typically reside only around portal triads (Figure 3) (128-
130), and, like DC in other peripheral sites, are able to efficiently capture, process and transport 
Ag to regional lymphoid tissues.  All three APC [liver sinusoidal endothelial cells (LSEC), 
Kupffer cells (KC), DC] internalize Ag by phagocytosis, receptor-mediated endocytosis, or 
pinocytosis, but their phenotypes differ considerably (9, 10, 131).  LSEC and KC express MHC 
Ags, costimulatory and adhesion molecules and make IL-1 and IFN-γ, suggesting that these cells 
are at a relatively mature stage (7, 9, 10, 131).  Freshly-isolated hepatic DC, on the other hand, 
are predominantly immature cells, expressing surface MHC but few costimulatory molecules 
necessary for T cell activation (132, 68, 133).  Compared with more mature bone marrow-




Figure 3.  Anatomy of hepatic sinusoids. 
The area between the LSEC and hepatocytes, where extracellular matrix and stellate cells reside, is called the space 
of Disse.  Kupffer cells and other immune cells are believed to extravasate through the LSEC fenestrations into the 
parenchyma.  DC normally reside only in the portal areas.  Abbreviations: BD, bile duct; DC, dendritic cell; H, 
hepatocyte; HA, hepatic artery; KC, Kupffer cell; LSEC, liver sinusoidal endothelial cell; PV, portal vein; and SC, 
stellate cell. 
1.2.1 The Role of the Liver Microenvironment and Hepatic DC in Tolerogenicity 
The immature phenotype of resident hepatic DC, coupled with the inherently unique liver 
microenvironment, potentially makes these APC different from DC in other tissue sites (i.e. BM, 
spleen).  Although not considered to be an immune privileged site, such as the anterior chamber 
of the eye or the testis, there are marked similarities between the cytokine milieu of the liver and 
that of these other sites.  KC and LSEC constitutively express the anti-inflammatory cytokines 
IL-10 and TGF-β, that are upregulated upon stress, while hepatocytes secrete IL-10 in response 
to autocrine and paracrine TGF-β (136, 137, 9, 131).  Lipocytes, another liver-specific cell 
population that includes Ito and stellate cells, also express increased TGF-β upon activation or 
stress (136).  These cytokines not only affect Th cell differentiation directly (skew to Th2) but 
also can confer tolerogenicity on DC and other APC by inhibiting their maturation and T cell 
stimulatory function.   
Although mature DC, rich in surface MHC and costimulatory molecules, are potent 
stimulators of immune (T cell) function, there is now much evidence that DC can be rendered 
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tolerogenic.  Thus exposure of replicating DC progenitors to IL-10 or TGF-β (138) generates DC 
that are suppressive or tolerogenic.  Steinbrink et al. (139) showed that culture of immature 
blood-derived human DC with IL-10 inhibited their maturation.  Similar results have been 
obtained with DC transduced with either IL-10 or TGF-β (140, 141).  Lack of adequate 
costimulatory molecule expression, either due to immaturity or exposure to costimulatory 
pathway blocking agents, can also result in tolerogenic DC, as shown in both allograft (142) and 
autoimmune disease (143) models.  
1.2.2 Phenotype of Hepatic DC 
Many different markers have been used to identify rodent and human DC, including those that 
are species-specific (Table 2).  While none are specific to hepatic DC, variations occur in the 
level of expression of certain markers compared with others.  CD11c is a common but not 
universal marker for DC detection in the murine system.  In addition, other markers, such as 
CD205, have been used by different groups to identify specific murine DC subsets.  The two 
well-characterized subsets identified in mouse liver as well as in lymphoid tissue, are the ‘so-
called’ myeloid- (CD8α-CD11b+) and lymphoid-related (CD8α+CD11b-) subsets of DC.  pDC 
have been identified in mouse lymphoid tissues (28-30) and more recently identified and 
characterized in the murine liver (69-71, 57).  These DC are CD11c+CD11b-CD19-B220+ and 
may play crucial roles in anti-viral immunity.   
DC have been generated in vitro from mouse liver stem/progenitor cells in response to 
GM-CSF.  These liver-derived DC progenitors (144, 145) are distinct in phenotype from DC 
freshly-isolated from normal liver and are CD11cloCD24+CD44+.  Maturation of DC is 
associated with upregulation of MHC II, CD80, and CD86 with CD205 being an additional 
marker used by some groups.  Lu et al. (146) have also shown that culture of normal murine 
hepatic non-parenchymal cells (NPC) with IL-3 and CD40L yields a unique population of DC-
like cells that are CD205hiCD11c-B220+CD19-.   
Less diversity has been reported to date for DC markers in the rat and human.  OX62, an 
integrin molecule, is commonly used to detect rat DC (147-149).  As in mice, maturity is 
monitored by surface expression of the CD28/CTLA4 ligands, CD80 and CD86.  Two distinct 
populations of mature rat hepatic DC have been identified:  1)  ED1+ED2-OX6+ and 2) ED1-
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ED2-OX6+.  In the human, DC are commonly MHC II+ and deficient in the CD28/CTLA4 
ligands while in an immature state.  Prickett et al. (130) found that human liver DC were also 
CD45+CD11a+CD18+. 
Thus it can be seen that there are similarities and disparities amongst hepatic DC 
populations.  Common features to all three species include the lack of or low expression of MHC 
II and CD28/CTLA4 ligands on immature DC, that are increased upon maturation.  CD11c and 
OX62 are generally considered the definitive markers for mouse and rat, respectively.   
1.2.3 Enumeration of Hepatic DC 
The normal murine liver has a relatively high total interstitial DC content, about 2-5 fold greater 
than that of other parenchymal organs, such as the kidney or heart (150).  However, when the 
density of MHC II+ DC between these organs is compared, the liver ranks as the lowest (150).   
Specific DC populations, such as the myeloid- and lymphoid-related subsets, studied in 
other tissues (151, 76, 152) (Table 2), can be found in normal mouse livers.  Previous studies 
have shown that these sub-populations constitute a low percentage of the total tissue-specific DC 
population.  The relative proportions of these two subsets in the liver are similar to those seen in 
other tissues (151, 76, 152, 68).  Each population constitutes ≤1% of the total normal liver NPC 
population (68).  
Liver DC can be isolated from NPC by collagenase digestion followed by metrizamide 
density centrifugation (153, 134, 68).  Although the total number of DC in the liver is greater 
than that of other parenchymal organs, there are still few cells to work with in comparison to 
lymphoid tissue.  This paucity of cells is especially evident if one wants to work with a specific 
DC subset.  Administration of recombinant human Flt3L, an endogenous hematopoietic growth 
factor, markedly increases the total number of hepatic DC (68).  Furthermore, the yield can be 
further increased by overnight culture of the isolated DC progenitors with GM-CSF.  Under such 
culture conditions, the percentage of both CD8α- and CD8α + DC can be increased to 10-15% of 
the total NPC population (68). 
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Markers References; Comments 
Mouse Immature CD11c+CD40loCD80loCD86loMHCIIlo (153, 154, 135, 131)  3 subsets: 
  1)  CD8α-CD11b+ 
2)  CD8α+CD11b-
3)  B220+CD11b-CD19-
(68, 155)     1)   Myeloid-related 
                    2)   Lymphoid-related 
(69-71, 57)  3)   Plasmacytoid 
  B220-CD11c+CD205-F4/80-  (156) 
  CD205+OX2+ (157, 158, 149) 
  CD11b+CD24+CD44+CD45+CD11clo 
CD16/32loCD40loCD80loCD86lo 
CD205loF4/80lo
(144, 145)  Generated from liver 
progenitor cells with GM-CSF; 
called liver derived DC progenitors. 
    
 Mature CD11c+MHC IIhiCD86hi  




    
 Other CD205hi B220+CD11c- CD19- (146) Generated from liver 
progenitor cells with IL-3 and 
CD40L.  Ig gene rearrangement 
occurs but no surface  expression.  
Activate then subsequently induce 
apoptosis of T cells. 
    
Rat Immature MHC II+ANAE-FcR- (159) ANAE= α-naphtylacetate 
esterase = a nonspecific esterase; 
FcR = Fc Receptor 
    
 Mature MHC IhiMHC IIhiCD54+OX62+ (147, 160, 161)   
  1)  ED1+ED2-OX6+
2)  ED1-ED2-OX6+
(162)  2 subsets of OX62+ cells 
  MHC II+CD54+OX62+CD90+
CTLA-4 Counterreceptor+
(148) 
  CD4+ (163, 164)  Variable expression is 
common in MHC II+ DC and 
peripheral tissues of rat 
    
Human Immature CD11a+ CD45+MHC II+ (130) 
  CD83loCD86loMHC IIlo (165) 
    
 Mature CD200+ (166) 
  CD83+CD86+ (167) 
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The phenotype of the DC obtained from Flt3L-mobilized mice resembles that of DC 
isolated from normal liver and in situ (153, 134, 144, 168, 157, 68).  Drakes et al. (157) showed 
that the administration of Flt3L did not change the phenotype of freshly-isolated hepatic DC, as 
defined earlier.  These Flt3L-treated DC, upon culture with GM-CSF and IL-4 or exposure to a 
maturation-inducing stimulus, such as extracellular matrix (ECM) protein, increased their surface 
costimulatory molecule expression and T cell allostimulatory activity (144, 169, 157, 170). 
The leukocyte content of the liver and its DC constituency in particular, appear to play an 
important role in transplant outcome.  Thus, when donor hepatic leukocytes either are drastically 
reduced (171-173) or greatly augmented (174, 175), a switch from tolerance to rejection occurs 
in murine liver transplantation.  In the case of donor leukocyte depletion, transplant tolerance can 
be restored by replacement of the donor leukocytes (172).  Thus, a balance appears to exist 
between the number of donor hepatic DC and liver tolerogenicity. 




Early studies showed that i.v. administration of colloidal carbon (128, 163, 176) or 
antibody-coated human red blood cells (159) did not result in phagocytosis by DC.  It was 
speculated that liver DC, unlike KC and LSEC (177, 178, 9), did not phagocytose these particles 
in vivo.  However, more recently, elegant studies in the rat by Matsuno et al. (160, 179) have 
shown that carbon-laden DC localize in the celiac nodes within 2 hours of the i.v. administration 
of carbon particles.  Furthermore, it was determined that immature DC were the major 
population of particle-laden cells that entered the hepatic lymph.  It was suggested that these 
phagocytic DC were recruited from the systemic circulation and were not part of the resident DC 
population.  Interestingly, Iyoda et al. (180) have reported that in mice, only the liver-resident 
CD8α+ DC subset exhibits phagocytic properties in situ.   
 T cell stimulation 
Murine liver DC progenitors cultured overnight with or without GM-CSF stimulate naïve 
allogeneic T cells (134, 174, 135).  Abe et al. (133) observed that the allostimulatory activity of 
immature liver-derived DC for memory T cells was not affected by administration of pro-
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inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) or IFN-γ.  However, addition 
of Ag (i.e. viral antigen; KLH, keyhole limpet hemocyanin) to immature hepatic DC induced 
upregulation of MHC II, costimulatory molecules, and T cell allostimulatory activity.  Khanna et 
al. (135) found that although cultured immature mouse liver-derived DC were weak stimulators 
of allogeneic naïve T cells in vitro, their in vivo administration to allogeneic recipients resulted 
in selectively increased IL-10 production within secondary lymphoid tissue.  By contrast, mature 
bone marrow-derived DC elicited increased IFN-γ but not IL-10 production.  Immature hepatic 
DC therefore resemble freshly-isolated immature respiratory tract DC that poorly stimulate 
allogeneic T cells and selectively induce Th2 responses (181).  These features of liver-derived 
DC are consistent with hepatic “tolerogenicity” and may play a role in immune response 
deviation following liver transplantation. 
There is as yet little documented information about the T cell stimulatory ability of 
purified freshly-isolated human liver DC.  Based on their immature phenotype in situ (182) 
(including lack of CD86) and the known properties of circulating peripheral blood DC with an 
immature phenotype (183), it is likely however that these cells are weak allostimulators.   
1.2.4.3 Chemotaxis 
Migration of DC to and from peripheral tissue depends on the production of chemokines 
(CC and CXC) and the expression of specific CR (CCR and CXCR).  Because leukocyte 
migration is a key event in infection and inflammation, chemokine biology is rapidly becoming 
an important area of study, in relation to elucidation of DC function.  Most chemokine receptors 
are promiscuous and can ligate a variety of different chemokines (184, 113, 185). 
In the case of hepatic DC, few studies have been conducted regarding specific chemokine 
and receptor expression.  Drakes et al. (186) showed that immature and mature liver-derived DC 
exhibited similar chemokines and receptors, although with differing levels of expression.  
Expression was similar to that detected on BM-derived DC.  As determined by RNase protection 
assay (RPA), the chemokine most strongly expressed by both immature and mature liver-derived 
DC was CCL5.  However, CCL3, CXCL1 (MIP-2), and CCL2 (MCP-1; monocyte 
chemoattractant protein-1) were also expressed by these liver-derived DC.  Receptors CCR1 and 
CCR2 were expressed at comparable levels on these liver DC.  CCL5 and CCL3 are among the 
various chemokines that bind CCR1, while CCL2 binds CCR2.  CCL3 expression was greatly 
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enhanced upon liver DC maturation and stimulation by bacterial LPS or naïve allogeneic T cells 
also induced chemotaxis of mature liver-derived DC.   
Shields et al. (187) found that CCR5, for which CCL3 is a ligand, is important in T cell 
recruitment in both hepatitis C virus (HCV)-infected and normal livers.  Goddard et al. (188) 
similarly observed the importance of CCR5 in T lymphocyte recruitment during the 
inflammatory response in human liver transplantation.  The presence of this receptor on T cells, 
coupled with the production of CCL3 by resident liver cells, implies the existence of DC-T cell 
interactions within the liver under normal and inflammatory conditions.  Further studies are 
needed to assess the role of chemokines and their receptors in regulation of hepatic DC migration 
and function. 
1.3 ETHANOL AND IMMUNITY 
Studies have consistently demonstrated an association between alcohol abuse and 
increased susceptibility to a variety of infectious diseases.  The rates of infection and severity of 
disease of alcohol abusers with bacterial pneumonia and tuberculosis are higher than 
nonalcoholics, even with antibiotics (Reviewed in 189).  Other studies have shown accelerated 
histologic and clinical progression of chronic liver disease in patients with chronic HCV and 
alcohol use (190, 191). 
Past analyses on the effects of chronic ethanol (EtOH) exposure on the immune system 
have shown that serum immunoglobulin levels are increased (192, 193), lymphocytes (including 
T, B, and NK cells) are reduced in numbers with alteration in subsets, T cells are persistently 
activated yet there is reduced cell-mediated immunity, and monocytes and neutrophils, while 
increased in numbers and in activation, have abnormal function (Reviewed in 189).  The 
abnormalities in cell function include altered phagocytosis and migration (194-196) and cytokine 
expression (Reviewed in 197).  In rats and mice, it has been shown that chronic EtOH feeding 
leads to increased NF-κB which can have numerous consequences on DC function (i.e. increased 
cytokine and chemokine secretion, maturation) (198, 199).  Others have shown in mice and in in 
vitro cell culture systems that EtOH affects other cell signaling pathways, such as attenuation of 
activation of STAT1 and STAT3 (Signal Transducer and Activator of Transcription) (200, 201).  
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It is likely that EtOH has multiple effects on cells which may include changes in phenotype, 
other signaling pathways, and downstream cellular functions in immune cells, all which may 
contribute to the mechanism by which EtOH exerts its immunosuppressive effects. 
1.3.1 Animal Models of Chronic Ethanol Administration 
Several murine models of chronic EtOH administration are currently being used by various 
investigators.  Each model has its advantages and disadvantages; however, each has its role in 
examining the effects of chronic EtOH exposure on the mouse system (Table 3).  It is important 
to note that many alcohol studies utilize the rat model.  Thus, many published studies, although 
studying chronic EtOH consumption, are not completely correlative in the mouse system as there 
are differences in the metabolism of EtOH and pathophysiology of EtOH disease between rodent 
models.  Indeed, it has been reported that rat and mice metabolize EtOH with different kinetics.  
Mice blood alcohol levels (BAL) had a sharper and more rapid rise compared to rats but were 
followed by a sharp and rapid decline in BAL.  In contrast, BAL in rats had more gradual rises 
and declines (202).    
1.3.1.1 Lieber-DeCarli Diet 
The Lieber-DeCarli (LD) diet is a totally liquid diet devised over fifty years ago to study 
alcohol consumption in an animal model while dietary caloric intake was controlled as well as 
allowing for isocaloric substitutions for pair feeding controls (Table 3) (203).  In rats and 
baboons, this model has proven to be useful in studying early liver injury (204, 205).  In these 
animals, steatosis and oxidative stress changes are found in the liver (204, 205).  Even more 
pronounced effects in the liver, such as fibrosis and inflammation, can be induced in rats when 
other drugs or agents, such as choline, methionine or Vitamin A, are added to the diet (204).    
In the mouse, the EtOH effects of the LD diet on the liver are not equivalent to the 
changes seen in the rat or baboon.  While steatosis occurs, as well as the presence of Mallory 
bodies - aggregates of intermediate filaments of prekeratin which are present in degenerative 
hepatocytes and are a classical finding of alcoholic hepatitis (but can be found in other liver 
disease states) - there are few other pathologic changes in mouse liver (204).  Further, mice have 





intake (206) or allowing mice free access to water in addition to the LD diet (207).  It has also 
been reported that the LD diet causes stress effects on mice (207).  While this model has its 
advantages, with no bias from caloric intake between EtOH-treated and control groups, the 
mortality rate, coupled with the non-physiological method of EtOH intake, have encouraged 
investigators to continue searching for an alternative mouse model.  
 Tsukamoto-French Model 
The Tsukamoto-French murine model (Table 3) essentially administers EtOH to mice 
intragastrically via permanent gastric cannulation, requiring surgical implantation (208-210).  
With this model, not only is steatosis in livers observed, but inflammation and pericentral 
necrosis is found (210).  Thus, this model is capable of inducing liver pathology similar to what 
is seen in human alcoholic liver disease.  However, the non-physiologic method of EtOH intake, 
surgical expertise required, and cost for maintenance of animals following surgery prohibit many 
groups from utilizing this murine model. 
 Meadows-Cook Model 
Meadows first described a chronic alcohol consumption murine model where mice were 
given 20% w/v EtOH ad libitum as their sole fluid source with free access to diet and water 
(211).  More recently, the Cook group modified the Meadows model by incorporating a one 
week acclimating period during which the EtOH concentration was increased in two stages to the 
final 20% w/v EtOH concentration (212).  This model has been reported to cause little stress 
effects, in contrast to the LD diet (207).  As seen in mice fed the LD diet, steatosis occurs in the 
liver, but no other pathologic changes (i.e. inflammation or necrosis) (212).  Thus, although 
lacking many of the late pathologic changes (i.e. inflammation or necrosis) that occur with 
human alcoholic disease, this model is less stressful to mice and more physiological in EtOH 
intake compared to the other murine models. 
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Table 3.  Murine models of chronic EtOH administration. 
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1.3.2 Ethanol and DC 
At present, there have been limited studies investigating EtOH’s effects on DC, and all of these 
studies have been confined to human peripheral blood monocyte-derived DC propagated in vitro 
(219, 220).  Szabo’s group have shown that monocyte-derived DC, cultured for 7 days with 25 
mM EtOH, have significantly reduced allostimulatory capacity in mixed leukocyte reaction 
(MLR), reduced expression of CD80 and CD86, as well as altered cytokine production, 
compared to control monocyte-derived DC (219, 220).  NFκB activation, which is upregulated 
during DC maturation, was not affected in response to LPS stimulation (220).  Further, it has 
been shown that when humans acutely intake EtOH, monocyte-derived DC propagated from 
their peripheral blood monocytes exhibited reduced allostimulatory capacity (221, 222, 220).  
Thus, EtOH exposure, both acute and chronic, inhibits the function of human monocyte-derived 
DC.  
Thus, even with the studies by the Szabo group, there is a dearth of knowledge on 
EtOH’s effects of DC differentiation and function.  Further, no studies to date have examined the 
effects of EtOH on murine DC, despite the increased use and role for the mouse model in 
studying EtOH’s effects on immune function.   
1.3.3 Ethanol and other leukocytes 
Most reports on EtOH’s effects on immune cells have focused on monocytes, macrophages, NK 
cells, and T cells.  Furthermore, while a few studies have examined the effects of chronic EtOH 
exposure, most studies to date have examined the acute effects of EtOH.  The predominant 
theme of these studies is that EtOH exposure, both acute and chronic, has significant inhibitory 
effects on the function of various leukocyte populations. 
Monocytes are precursor cells that already possess migratory, chemotactic, pinocytotic 
and phagocytic capacity.  Depending upon environmental signals, monocytes will differentiate 
into DC or macrophages (223).  Monocytes from human volunteers who consumed acute 
amounts of alcohol (vodka, 2 ml/kg, in a total volume of 300 ml orange juice, over 30 min) had 
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significantly reduced allostimulatory capacity compared to control monocytes from the same 
volunteers (taken before drinking) (221, 222, 220).  Further, monocytes, when treated with EtOH 
and stimulated with LPS in vitro, exhibited inhibited NFκB activation (224, 225, 220) and 
suppressed TNF-α secretion (226, 227, 225, 228).  This finding of suppressed TNFα with acute 
EtOH exposure is in contrast to findings with chronic EtOH exposure, where there is enhanced 
TNFα production in response to LPS (229).   
TNF-α production in response to acute versus chronic EtOH exposure, similar to that of 
monocytes, is seen with macrophages (226, 230).  Further functional changes in macrophages 
include decreased phagocytosis (231-233), impaired cytokine production (234-236),  and NFκB 
activation (237, 238).  Production of reactive oxygen species is important for macrophage 
function.  It has been shown that acute and chronic EtOH exposure decreases nitric oxide (239), 
superoxide anion (although differentially depending upon stimuli) (240, 239), and hydrogen 
peroxide (240) production by alveolar macrophages.  However, in the liver, overproduction of 
oxygen radicals has been suggested as a pathologic mechanism for alcohol-induced liver 
damage.  Accordingly, KC have been shown to be the source of increased production of EtOH-
induced superoxide anion with both acute and chronic EtOH exposure (241-244).   Thus, 
depending on the location of the resident macrophage, EtOH has differential effects on the 
production of superoxide anion.   
Alcohol consumption has been associated with increased morbidity and mortality related 
to malignancies (245, 246).  Thus, there is great interest in examining the effects of EtOH on NK 
cell functions, which are involved in the prevention of tumor development.  Current reports on 
this topic are conflicting - while most studies show that NK cell functions (i.e. cytotoxicity) are 
inhibited by EtOH (247-251), a few reports have shown no effect (252) or increased (253) NK 
cell function with EtOH treatment.  It should be noted that a seeming tumor-promoting effect of 
EtOH is transient and within ± 24 hours of EtOH exposure, there was no difference in numbers 
of  tumor metastases between control and EtOH-fed groups (254). 
It has consistently been reported that human chronic alcoholics have decreased 
circulating lymphocytes (255, 256).  Similarly, it has been shown that chronic EtOH exposure in 
mice results in decreased cells numbers in thymus and spleen (257, 258).  Further, T cells from 
human chronic alcoholics exhibit reduced proliferation to stimulation which could not be 
restored by exogenous IL-2 or IL-1 (259).  In rat models, it has been shown that T cells from 
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chronic EtOH-treated rats fail to proliferate in response to IL-2 and is not due to decreased IL-2 
receptor expression.  It has also been suggested that the impaired immune responses seen in 
chronic alcoholics is due to skewing of the Th1/Th2 responses – particularly, a decrease in Th1.  
Currently, although several reports suggest that chronic EtOH-treatment skews towards Th2 
responses, the data are still inconclusive.  In support of the Th2 skewing theory, when mice were 
infected with Klebsiella pneumoniae, which is cleared with appropriate Th1 responses, chronic-
EtOH fed mice displayed Th2 cytokine skewing (increased IL-10 with decreased IL-12 and 
IFNγ) with concomitant impaired clearance of infection (260).  Further, other reports have shown 
that EtOH treatment inhibits Th1-associated IL-12 and IFNγ production (261, 262) as well as 
increased systemic serum IgE (Th2) levels (262).  However, in a different study, chronic EtOH-
fed mice were infected with Leishmania major or Strongyloides stercoralis with no difference in 
clearance of infection between EtOH and control groups (263).  Although there was no defect in 
the Th1 response to clear L. major, mice given longer EtOH diets (5 vs. 13 weeks) were 
associated with increased serum IgG1 (Th2 Ab) and decreased serum IgG2a (Th1 Ab), indicating 
a general shift to Th2 responses (263).  Thus, length of EtOH exposure is relevant in potential 
Th1/Th2 skewing although the functional importance of the Th1/Th2 skewing is unknown as 
EtOH-fed mice were able to clear infection as well as control mice.   
Another aspect to consider in the study of T cells in chronic EtOH consumers is the status 
of their activation.  Human alcoholics have been shown to have increased CD69 (264) and CD25 
(265, 264) expression, both markers of activation, on T cells.  In the mouse model of chronic 
EtOH consumption, it was shown that CD44, upregulated on T cells upon activation, expression 
is increased (212).  Overall, the mechanism by which EtOH affects T cell proliferation and 
function is not well understood.   
1.3.4 Ethanol and leukocyte migration 
It is known that chronic EtOH consumption in humans is associated with increased migration of 
polymorphonuclear neutrophils (PMN) into the liver, contributing to the pathogenesis of 
alcoholic liver disease.  One theory for the increased leukocyte sequestration and subsequent 
injury within the liver is that EtOH causes alterations in chemotactic factors and adhesion 
molecules which contribute to hepatic injury (266, 267).  Indeed, it has been shown that chronic 
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EtOH feeding in rats causes increased levels of endotoxin (267), likely due to increased gut 
permeability from EtOH consumption, increased serum CXCR2/MIP-2 (high production by KC) 
(267), and significantly increased expression of CD18 on PMN (268) and CD54 on hepatocytes, 
LSEC, and KC (267).  When an anti-CD18 monoclonal (m)Ab was administered in the rat 
model, there was attenuation of hepatic injury, indicating a contribution of adhesion molecules in 
the initiation of the hepatic injury (267).   Other studies have imaged hepatic sinusoids and 
mesenteric venules in the rat model of chronic EtOH consumption and similarly found that LFA-
1, CD18 and CD54 play a significant role in EtOH-induced increases in leukocyte adherence and 
extravasation (269, 266, 270).   
In an acute EtOH model, it was shown that EtOH suppressed leukocyte accumulation and 
EC adhesion molecule expression in a dose-dependent manner (271).  Further, it was shown that 
EtOH inhibited TNF-mediated activation of EC, as determined by suppressed adhesion molecule 
expression and chemokine production, and inhibited leukocyte adhesion in vitro (271).  The 
reduced adhesion molecule expression and subsequent reduced leukocyte adhesion with acute 
EtOH exposure is consistent with reports in humans that show similar findings with acute EtOH 
(272).  Similarly, the findings described above using a chronic EtOH model are also in 
agreement with human studies that have shown significantly higher serum levels of adhesion 
molecules in chronic alcoholics compared to non-drinkers or moderate drinkers (272).  Thus, it is 
likely that adhesion molecule expression and chemokine production are affected by EtOH 
exposure, and these alterations may contribute to hepatic injury and inflammatory responses. 
 
1.4 SCOPE OF THE THESIS 
The immune compromised status of alcohol abusers may be in part due to impaired function of 
DC, the most highly specialized APC, in response to TLR ligation.  Human alcoholics have been 
shown to have higher incidence of infection to bacterial pneumonia and tuberculosis (189).  
Downstream effects of TLR9, which recognizes bacterial DNA and has been shown to induce 
DC responses, ligation may be affected on DC, contributing to the impaired immune response to 
bacterial infection.  In these studies, we examine the effects of prolonged EtOH exposure on 
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BMDC, liver and spleen DC subsets in response to TLR9 activation.  We have found that 
Prolonged EtOH exposure: has differential effects on cosignaling molecule expression on BM, 
liver and spleen DC; reduces the stimulatory capacity of BM and spleen DC in vitro and in vivo; 
reduces the stimulatory capacity of resting but not stimulated hepatic DC in vitro; increases 
expression of CD11a on hepatic DC with no effects on expression of adhesion molecules on 
splenic DC in vivo; inhibits functional CCR7 in hepatic and splenic DC as measured by in vitro 
chemotaxis to CCL19; and increases the number of hepatic DC migrating to DLN compared to 
control hepatic DC whereas migration of splenic DC is unaffected by EtOH exposure.  Thus, 
hepatic and splenic DC are shown to be differentially affected by chronic EtOH exposure.  In 
vivo assessment of immune reactivity by specific lytic activity, Ag-induced cytokine production 
by CD4 and CD8 T cells, as well as serum IgG production reveals no quantifiable differences 
between control and EtOH-fed mice, which may be affected by length of EtOH exposure in vivo.  
Thus, the effects of chronic EtOH exposure on DC are complex and differ depending on the 
subset, location, and activation status.  The interrelationship between these effects and immune 













2.0  EFFECTS OF CHRONIC ETHANOL EXPOSURE ON THE DEVELOPMENT, 
COSIGNALING MOLECULE EXPRESSION, AND FUNCTION OF PLASMACYTOID AND 
MYELOID DENDRITIC CELLS GENERATED FROM MURINE BONE MARROW2 
2.1 INTRODUCTION 
The immunobiology of plasmacytoid and myeloid DC has generated much attention as a result of 
their potential for therapeutic application (273-275, 40).  Manipulation and targeting of DC to 
induce specific immune responses has long been investigated and various strategies are now 
being tested in the clinical setting (276).  With the widespread availability of growth factors and 
the technology to produce large quantities of DC from BM precursors, the use of various DC 
subsets will surely be further investigated for their therapeutic potential.   
Various drug agents have been used to modify the function of BMDC with varying 
outcomes in T cell activation.  Immunosuppressive drugs such as rapamycin (277) and FK506 
(278) have been shown to inhibit the T cell stimulatory capacity of BMDC in distinct manners.  
Immunosuppressive drugs are used extensively in the treatment of various chronic inflammatory 
diseases, including allograft rejection.  The influence of these drugs on DC development, 
maturation, and function is under extensive study (279).  There is strong evidence that these and 
other pharmacologic agents may affect DC.  Several drugs and vitamins have been studied in 
detail (i.e. CsA, corticosteroids, 1α,25-Dihydroxyvitamin D3) while some newer drugs (i.e. the 
deoxyspergualin derivative LF15-0915) also have inhibitory effects on DC maturation which 
may have therapeutic implications (279).  The influence of these common drugs and vitamins on 
DC provides potential mechanisms by which DC-T cell interactions can be manipulated to 
generate T cell unresponsiveness or regulation.   
                                                 
2 Data and Text excerpted from (57). 
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Presently, there have been limited studies investigating EtOH’s effects on the 
development and function of DC.  Studies on EtOH administration have revealed numerous 
inhibitory effects on functions of human blood monocytes (280, 227, 228, 221), monocyte-
derived DC (219, 220) and rodent macrophages (226, 234-236).  In murine in vivo alcohol 
intoxication models, studies to date have focused primarily on the deleterious effects of acute 
and chronic alcohol administration on macrophages (281, 234-236) and of chronic EtOH 
consumption on splenic T cells (212, 213).  Analyses thus far of the influence of prolonged 
EtOH exposure on DC differentiation and function have been confined to human peripheral 
blood monocyte-derived DC propagated in vitro (219, 220).  No studies to date have examined 
the effects of chronic EtOH administration on murine DC subsets despite the increased use of the 
mouse model for alcohol and immune function studies. 
We first sought to investigate the effects of prolonged EtOH exposure on the 
development, phenotype, and function of BM-derived DC subsets.  Our studies reveal that while 
EtOH inhibits both the generation of bone marrow-derived (BM)mDC and BMpDC in vitro, 
pDC, that are important sources of IFNα (282, 27), appear to be particularly susceptible.  EtOH 
also differentially affects the expression of classic and recently-identified B7 family cosignaling 
molecules on resting DC subsets and following CpG oligodeoxynucleotide (CpG-ODN) 
stimulation.  Further, EtOH-exposed BMDC have reduced stimulatory capacity for naïve T cells.  
Interestingly, BMDC exposed to EtOH elicit elevated levels of IL-10 production by allogeneic T 
cells.    
2.2 MATERIALS AND METHODS 
2.2.1 Animals 
Six- to eight-week old C57BL/10 (B10; H2Kb), BALB/c (H2Kd), and C3H/HeJ (C3H; H2Kk) 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained in the 
specific pathogen-free Central Animal Facility of the University of Pittsburgh Medical Center.  
Experiments were conducted under an Institutional Animal Care and Use Committee-approved 
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protocol.  The animals were fed a diet of Purina rodent chow (Ralston Purina, St. Louis, MO) 
and received tap water ad libitum unless specified.   
2.2.2 Media, reagents, and Abs 
RPMI-1640 was supplemented with 10% or 20% v/v heat-inactivated fetal calf serum (FCS; 
Atlanta Biologicals, Inc., Norcross, GA), 0.1 mM non-essential amino acids, 2 mM L-glutamine, 
sodium pyruvate, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 20 µM 2-β mercaptoethanol 
(complete medium) (all reagents from Life Technologies, Gaithersburg, MD).  Chinese hamster 
ovary cell-derived human recombinant fms-like tyrosine kinase 3 ligand (Flt3L) was provided by 
Amgen (Seattle, WA).  The TLR9 ligands CpG-DNA class A (CpG-A; ODN2336), CpG-B 
(ODN1826: TCCATGACGTTCCTGACGTT) and CpG-DNA control (ODN2138) were certified 
endotoxin-free and obtained from Coley Pharmaceutical (Wellesley, MA).  Monoclonal 
antibodies (mAbs) used for flow cytometry and cell sorting were hamster anti-mouse CD11c 
[HL3; biotin- or fluorescein isothiocyanate (FITC)-conjugated], hamster IgM anti-CD40 [HM40-
3; phycoerythrin (PE)-conjugated], rat anti-CD11b (M1/70; biotin-, FITC- or PE-conjugated), 
anti-CD45R/B220 (RA3-6B2; biotin-, FITC-, or CyChrome-conjugated) and PE-conjugated anti-
CD80 (16-10A1), anti-CD86 (GL1), anti-B7-H1 (MIH5; eBioscience, San Diego, CA), anti-
CD49b α2 integrin (DX5; eBioscience); mouse anti-H2Kb (AF6-88.5) and anti-IAb β-chain 
(AF6-120.1) (all mAbs from BD PharMingen, San Diego, CA, unless specified).  Isotype-
matched control Igs and streptavidin (SA)-CyChrome were from BD PharMingen.  Herpes 
Simplex Virus (HSV)-1 (RE strain of HSV-1) was a kind gift from Dr. R.L. Hendricks 
(University of Pittsburgh). 
2.2.3 Generation and purification of BM-derived DC subsets 
Bone marrow (BM)-derived DC were generated as described (40), with minor modifications.  
Briefly, B10 BM cells were cultured for 8 days in complete medium in 200 ng/ml Flt3L, with or 
without EtOH.  On day 4, 50% of the supernatant was replaced with fresh cytokine-containing 
medium and fresh EtOH.  EtOH-treated cultures were maintained in a chronic EtOH incubator 
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system (229) to maintain a constant EtOH concentration.  EtOH concentrations were measured 
daily using the nicotinamide adenine dinucleotide (NAD)-alcohol dehydrogenase assay (Pointe 
Scientific, Inc., Canton, MI) to ensure maintenance of EtOH levels.  On day 8, the cells were 
analyzed by flow cytometry, enriched for CD11c+ cells by incubation with anti-mouse CD11c-
coated immunomagnetic beads (10 µl/107 cells; Miltenyi Biotec, Auburn, CA) for 15 min at 4°C, 
then positively selected by passage through a paramagnetic column (MACS; Miltenyi Biotec), 
yielding a highly-enriched (≥ 90%) CD11c+ population, or flow-sorted as described below.  
2.2.4 Flow cytometry and cell sorting 
Flow cytometric analyses and cell sorting were performed as described (68, 79) with minor 
modifications.  To avoid non-specific Ab binding, the cells were preincubated with 10% v/v 
normal goat serum for 20 min at 4°C, then incubated with the mAbs indicated for 45 min at 4°C.  
Cells incubated with the appropriate isotype-matched control Igs served as negative controls.  
After washing, biotin-conjugated mAbs were revealed with second step streptavidin-CyChrome.  
The cells were then analyzed using a Coulter EPICS XL.MCL flow cytometer (Beckman 
Coulter, Miami, FL).  For sorting, CD11c bead-enriched cell suspensions were incubated with 
anti-CD11c-FITC, anti-CD11b-PE, and anti-CD45R/B220-CyChrome for 45 min at 4°C.  
CD11cintB220+CD11b- (pDC) and CD11c+B220-CD11b+ cells (mDC) were then sorted to ≥99% 
purity using a MoFlo® cell sorter (Cytomation, Fort Collins, CO).   
2.2.5 Analysis of apoptosis and necrosis 
BMDC exposed to 50 mM EtOH in culture for 1, 4, or 6 days were analyzed for apoptosis by 
staining of phosphatidylserine translocation with FITC-annexin V in combination with vital dye 
Propidium Iodide (PI) according to the manufacturer’s instructions (BD PharMingen).  Cells 
were costained with CD11c to allow for specific analysis of DC by flow cytometry. 
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2.2.6 Detection of TLR9 expression by Polymerase Chain Reaction 
TRIzol LS Reagent (Life Technologies, Gaithersburg, MD) was added to the bead-purified 
BMDC suspensions and RNA extracted according to manufacturer's instructions. Before reverse 
transcription, digestion of DNA was performed with DNase I (Life Technologies). cDNA was 
synthesized with oligo(dT) as primer using Superscript kit (Life Technologies). Amplication was 
performed using the following primers; TLR9 (sense) TCCCTGTATAGAATGTG; (anti-sense) 
TGGAGGCGTGAGAG. HPRT (sense) GTAATGATCAGTCAACGGGGGAC; (anti-sense) 
CCAGCAAGCTTGCAACCTTAACCA. The samples were amplified for 35 cycles at different 
annealing temperatures (TLR9, 54°C,: HPRT, 55°C) by a GeneAmp PCR system 2400 (Boston, 
MA). PCR products were analyzed on agarose gels stained with ethidium bromide and 
photographed. 
2.2.7 Mixed Leukocyte Reaction (MLR) 
Spleen cell suspensions from C3H mice were depleted of red blood cells by NH4Cl treatment, 
resuspended in warm (37°C) complete medium, then passed over a nylon wool column (37°C for 
45 min) to enrich for T cells (purity >85%).  Two x 105 purified C3H T cells were stimulated 
with graded numbers of γ-irradiated (20 Gy), bead-purified or flow-sorted DC in complete 
medium in round-bottom, 96-well plates (Corning, Acton, MA).  [3H]TdR (1µCi) was added to 
each well for the final 16 h of 72 h cultures.  Cultures were harvested using a multiple well 
harvester and [3H]TdR uptake determined using a liquid scintillation counter.  Tests were 
conducted in triplicate and results expressed as mean counts per minute (cpm) ± 1 standard 
deviation (SD).   
2.2.8 Adoptive Cell Transfer 
Five x 105 bead-purified B10 DC were injected s.c. into one hind footpad of normal allogeneic 
(BALB/c) mice.  Six days later, popliteal lymph node cell suspensions were prepared and the 
cells cultured in 96-well, round-bottom plates at 2 x 105 cells/well in complete medium in the 
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presence of 2 x 105 γ-irradiated (20 Gy) donor or third party splenocytes.  After 72 h, 
supernatants were harvested and cytokine concentrations measured by enzyme linked 
immunosorbent assay (ELISA).  T cell proliferation was quantified by [3H]TdR incorporation, as 
described above.   
2.2.9 Cytokine Quantitation 
IFNα (PBL Biomedical Labs, Piscataway, NJ), IFNγ, IL-10 and IL-12p70 (R&D Systems, Inc., 
Minneapolis, MN) were quantified by ELISA using commercial kits from Biolegend (San Diego, 
CA) unless otherwise specified, and following the manufacturer’s recommended procedures.  
The detection limits were 12.5 pg/ml for IFNα, 4.0 pg/ml for IFNγ, 30 pg/ml for IL-10, and 7.8 
pg/ml for IL-12p70.    
2.2.10 Western blot analysis 
Cell extracts (10 µg/lane) and positive controls were separated electrophoretically on 10% w/v 
sodium dodecyl sulfate-polyacrylamide gels, as described (283).  Proteins were electroblotted to 
PolyScreen polyvinylidene fluoride (PVDF) membranes (Perkin Elmer Life Sciences, Inc., 
Boston, MA) at 200 mA for 1 h.  Blots were blocked for 30 min at room temperature with 5% 
nonfat dry milk in 50 mM Tris-HCl (pH 7.5), 200 mM NaCl, Tris-buffered Saline and, 0.05% 
Tween-20 (TBST).  After five 2 min washes with TBST, membranes were incubated overnight at 
4ºC with mouse Ab to indoleamine 2,3-dioxygenase (IDO; Chemicon International, Temecula, 
CA), diluted to 1:1000, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), diluted to 
1:1000.  After subsequent washes with TBST, the membrane was incubated for 1 h with 
peroxidase-conjugated goat anti-mouse secondary Ab, diluted 1:10,000 (Jackson 
Immunoresearch, West Grove, PA).  Abs were diluted in TBST.  Membranes were developed in 
Western Lightning Chemiluminescence reagent (Perkin Elmer Lifer Sciences, Inc.) followed by 
exposure to Kodak Biomax MS Film (Rochester, NY).  After the film was developed, Western 




The significances of differences between means were determined using Student’s unpaired ‘t’ 
test or Fisher’s protected least significant difference test.  A value of p < 0.05 was considered 
significant.  In certain experiments (Figures 5, 6, 7, 10, 18, 19 and 21), there was variability in 
the expression of various molecules (percent positive cells, MFI, and/or mRNA or protein levels 
visualized by PCR or Western blot, respectively) between repeat experiments, and the data 
shown are thus from one experiment representative of three.  In MLR assays, there was 
variability in the level of proliferation of naïve T cells between the three experiments.  However, 
in each of the three experiments, the same statistical significance was found between 
experimental and control groups.  Thus, the figure shows one experiment representative of three 
experiments. 
2.3 RESULTS 
2.3.1 EtOH inhibits the generation of DC subsets from murine bone marrow 
The concomitant generation of multiple DC subsets in the presence of EtOH has not been 
examined.  To obtain adequate numbers of DC that included both mDC and pDC, B10 BM cells 
were cultured with the endogenous DC poietin Flt3L, a cytokine that stimulates the expansion 
and differentiation of immune cells of myeloid and lymphoid lineages, as described in the 
Materials and Methods.  We tested the influence of prolonged exposure (8 d) to various, 
physiologically relevant concentrations of EtOH (0-100 mM) on the development of both DC 
subsets.  In control (untreated) cultures, three to four-fold as many mDC as pDC were generated 
over the 8-day culture period (Figure 4A, B).  The yield of both mDC and pDC was reduced 
significantly and in a dose-related manner at EtOH concentrations >25 mM (Figure 4A, B).  
However, the two subsets consistently exhibited different sensitivities to EtOH, with pDC being 
more vulnerable than mDC.  pDC were susceptible at concentrations ≥25 mM (p<0.05), whereas 
mDC were reduced significantly in number at ≥50 mM (p<0.05).  Dotplots of the incidences of 
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CD11c+B220+ pDC and CD11c+CD11b+ mDC in cultures under increasing EtOH concentrations 
(Figure 4C) confirm the preferential inhibitory effect on the pDC subset.  Although the incidence 
of mDC showed a marked increase between 75 and 100 mM EtOH, the overall numbers of 
CD11c+ cells decreased substantially.  As both subsets were affected significantly at 50 mM, this 
concentration was used for all subsequent in vitro experiments.  Flow cytometric analysis of 
BMDC with Annexin V/PI at various timepoints (Days 0, 1, 4, and 6) revealed no significant 
difference in the incidence of apoptosis or necrosis between the control and EtOH-treated groups 
(Table 4).  Thus, it is unlikely that the observed inhibition of mDC and pDC generation was due 



















































































































































Figure 4.  The absolute number of B10 pDC and mDC generated in vitro in response to Flt3L decreases with 
EtOH concentration in a dose-related manner, with selective depletion of pDC.   
Flt3L-stimulated BM cells were exposed to various concentrations of EtOH from the start of culture as described in 
the Materials and Methods.  Day 8 cultures were labeled with anti-CD11c (biotin-conjugated; revealed with SA-
CyChrome), anti-CD45R/B220 (FITC-conjugated) and anti-CD11b (PE-conjugated).  (A,B), cells were gated on 
CD11c and analyzed for expression of B220+ (pDC; A) or CD11b+ (mDC; B).  Bar charts show the absolute number 
of cells harvested per well, based on percentage positive cells.   (C), day 8 cultures were labeled as above and gated 
on CD11c+ cells.  Dotplots show the distribution of CD11c+B220+ and CD11c+CD11b+ subsets.  (A,B), data were 
obtained from 3 experiments. *, p < 0.05; in comparison to control.  (C), data are from one experiment 
representative of 3 performed. 
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Data are from one experiment representative of 3 performed. 
2.3.2 Prolonged exposure to EtOH does not affect the expression of TLR9 mRNA  
It is currently unknown whether EtOH exposure affects TLR9 expression.  Alteration in the 
expression of this receptor could potentially affect stimulation through the receptor and affect 
subsequent functional analysis of DC after TLR9 ligation.  Thus, TLR9 mRNA expression by 
PCR was assessed for control and EtOH-exposed (50 mM, 8d) bulk BMDC.  PCR analysis 



















Figure 5.  TLR9 mRNA expression by BMDC is not affected by prolonged EtOH exposure. 
Flt3L-stimulated BM cells were exposed to 0 (Control) or 50 mM EtOH for 8 days of culture.  RNA was extracted 
from CD11c-bead purified DC and analyzed by PCR for TLR9 and HPRT expression.  Data are from one 
experiment representative of 3 performed. 
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2.3.3 Prolonged exposure to EtOH selectively modulates B7 family cosignaling molecule 
expression on unstimulated DC subsets and in response to CpG stimulation 
BMDC propagated in the presence of 50 mM EtOH exhibited reduced cell surface expression of 
CD40 and the classic B7 family costimulatory molecules, CD80 and CD86 (Figure 6A-C).  The 
extent of reduction in costimulatory molecule expression on both mDC and pDC was dependent 
on the length of exposure to EtOH; longer periods of exposure (≥72h) affected expression more 
markedly.  By contrast, cell surface MHC class I and MHC class II levels were not affected 
significantly (unpublished results).  The strikingly enhanced expression of CD40, CD80 and 
CD86 induced on both DC subsets by CpG stimulation was also inhibited by exposure to EtOH.  
CD40 expression appeared to be the most sensitive to the inhibitory effects of EtOH, with 
reduced expression evident at ≥24h of exposure, whereas CD80 and CD86 levels were reduced 
on cells exposed to EtOH for ≥48h (Figure 6).  Variablity in percent positive cells and MFI was 
seen between different BM cell cultures; however, the trends reported were consistent.  Thus, the 
data in Figure 6 are from one experiment representative of three.  
CD274/B7-H1, is a recently-characterized B7 superfamily coinhibitory molecule (284-
288). It is expressed on pDC (289) and mDC (290) and increased upon DC stimulation.  
Interestingly, and in contrast to the classic costimulatory molecules, basal CD274 expression was 
not affected by exposure of the BMDC to 50 mM EtOH for up to 8 days (Figure 6D-F).  
Furthermore, no consistent or significant effect of EtOH was observed on the markedly increased 
CD274 expression observed on either DC subset exposed to CpG.  When the ratio of CD274 to 
either CD80 or CD86 was examined, a progressive increase was observed with prolonged 
exposure to EtOH (Table 5). 
The reversibility of the effects of EtOH on the expression of costimulatory molecules was 
also examined.  BMDC cultures were set up as described, with or without EtOH treatment (8 
days; 50 mM).  After 8 days, both groups were maintained in culture under the same conditions, 
but with no EtOH treatment.  The DC were stimulated with CpG at various timepoints (0, 24, 
48h) after EtOH removal and mDC and pDC analyzed for costimulatory molecule expression.  
The results showed that the effects of EtOH on BM-derived mDC and pDC were not readily 
reversed, as the inhibitory effects of EtOH on BMDC costimulatory molecule expression were 
































































































































0 24h 48h 72h 8d




















0 24h 48h 72h 8d
E
//


















0 24h 48h 72h 8d
//
F







































Figure 6.  Expression of (A-C) classic costimulatory molecules (CD40, CD80, and CD86) on B10 DC subsets is 
reduced with prolonged exposure to EtOH, whereas expression of the (D-F) alternative cosignaling molecule 
CD274/B7-H1/PD-L1 is unaffected, even after prolonged exposure to EtOH. 
Flt3L-stimulated BM cell cultures were exposed for various periods to EtOH (50 mM), with or without CpG 
stimulation before FACS analysis 16 h later.  Day 8 cultures were labeled with anti-CD11c (FITC-conjugated) and 
anti-CD45R/B220 (CyChrome-conjugated) or anti-CD11b (biotin-conjugated and revealed with SA-CyChrome), 
and either (A-C) anti-CD40, -CD80, -CD86, or (D-F) -B7-H1 (all PE-conjugated).  Cells were gated on (A, D), 
CD11c+ cells, (B, E), CD11c+B220+ cells (pDC) or (C,F), CD11c+B220- cells and expression of (A-C) CD40, CD80, 
CD86, or (D-F) B7-H1 analyzed.  Bar charts show percent positive cells for the molecules indicated.  Results are 
from one experiment representative of three performed. 
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Table 5.  Ratio of CD274/B7-H1/PD-L1 to CD80 or CD86 on BM-derived DC increases with prolonged 






















































Data from Figure 2 (0h, 48h, and 8d of EtOH exposure) are presented as ratios between percent positive cells for 











Figure 7.  The effects of prolonged EtOH exposure on CD80, CD86 and MHCII expression are not readily 
reversible. 
Flt3L-stimulated BM cell cultures were exposed to EtOH (50 mM) for 8 days after which EtOH was removed from 
cultures.  Cells were stimulated with CpG 16 h prior to FACS analysis.  Day 8 and day 10 cultures were labeled with 
anti-CD11c (FITC-conjugated) and anti-CD45R/B220 (CyChrome-conjugated) or anti-CD11b (biotin-conjugated 
and revealed with SA-CyChrome), and either anti-CD80, -CD86, or -IAb (all PE-conjugated).  Cells were gated on 
CD11c+B220+ cells (pDC) or CD11c+CD11b+ cells (mDC) and expression of CD80, CD86, or IAb analyzed.  Day 8 
EtOH-DC are represented by the shaded histogram and 10 d (last 2 d no EtOH) EtOH-DC by the open dotted outline 
histogram.  Background isotype control staining is represented by the open black outline histogram.  Results are 
from one experiment representative of three performed. 
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2.3.4 EtOH-treated DC produce less IL-12p70 in response to CpG stimulation and EtOH-
treated DC subsets are poor stimulators of naïve T cell proliferation in vitro 
The influence of EtOH treatment on the capacity of B10 BMDC to produce IL-12p70, a potent 
inducer of T cell proliferation, was evaluated.  BMDC were bead-purified, stimulated overnight 
with CpG and culture supernatants assessed for IL-12p70 production, as shown in Figure 8A.  
EtOH-exposed BMDC produced significantly less IL-12 compared to control DC (Figure 8).  
Interestingly, production of IFNα in response to CpG-A stimulation was unaffected in BMpDC 
(Figure 9).  To assess the capacity of EtOH-treated control, CpG- or HSV-stimulated B10 DC to 
stimulate naïve, allogeneic (C3H) T cells, mDC and pDC from control or EtOH-treated BM DC 
cultures were flow-sorted to >95% purity.  CpG was added 16 h before DC sorting, whereas 
HSV was added to flow-sorted DC for 16 h before testing their function in MLR.  As expected, 
unstimulated pDC were comparatively poor inducers of naïve allogeneic T cell proliferation 
(Figure 8). By contrast, CpG-stimulated or HSV-infected pDC were much more efficient T cell 
stimulators.  Pre-exposure of the pDC to EtOH (50 mM) strikingly reduced their allostimulatory 
capacity (Figure 8B, D).  mDC were more efficient T cell stimulators than pDC, but EtOH 
exposure markedly inhibited the allostimulatory activity of control, CpG- or HSV- stimulated 





































































































































































Figure 8.  Exposure of B10 BMDC to EtOH significantly reduces their IL-12 production in response to CpG 
and reduces the stimulatory capacity of pDC and mDC for naïve allogeneic (C3H) T cells. 
BM cells were cultured in Flt3L, with or without 50 mM EtOH for 8 days, and with or without CpG (2 µg/ml) or 
HSV (10 pfu/cell) stimulation.  (A), supernatants from 16h CpG-stimulated, bead-purified B10 CD11c+ DC were 
analyzed for IL-12p70 production.  Results are from three experiments.  (B,C), cells were stimulated with CpG 16 h 
prior to sorting.  (D,E), alternatively, pDC or mDC were flow-sorted, infected with HSV for 16 h, then used as 
stimulators in MLR.  Flow-sorted pDC (CD11c+CD11b-B220+) or mDC (CD11c+CD11b+B220-) were irradiated (20 
Gy) and graded numbers co-cultured with 2x105 nylon wool-purified allogeneic C3H T cells for 72 h, as described 
in the Materials and Methods.  [3H]TdR was added for the final 16 h of culture.  Results are from one experiment 





















Figure 9.  IFN-α production by BMpDC in response to CpG-A stimulation is unaffected by EtOH exposure. 
BM cells were cultured in Flt3L, with or without 50 mM EtOH for 8 days and flow-sorted for pDC (CD11c+CD11b-
B220+) as described in Materials and Methods.  BMpDC were stimulated for 16 h with CpG-A and supernatants 





2.3.5 EtOH-treated DC exhibit unimpaired IDO production 
Recently, studies have focused on the role of the tryptophan-catabolizing enzyme indoleamine 2, 
3-dioxygenase (IDO) in inhibiting T cell proliferation (291-293), and expression of IDO by DC 
has been associated with inhibition of T cell function and survival (38, 294).  We measured IDO 
protein levels by western blot and found that EtOH-treated, unstimulated or CpG-stimulated 
BMDC, spleen DC and liver DC (50 mM) exhibited unimpaired IDO production (Figure 10).  
Thus, this enzyme is unlikely to play a role in the observed impaired T cell allostimulatory 








































Figure 10.  IDO production by  BMDC is unchanged by EtOH exposure in vitro.   
Protein was isolated from control or CpG-stimulated, bead-purified CD11c+ DC from Flt3L-stimulated B10 cell 
cultures propagated with or without 50 mM EtOH for 8 days.  Western blot analysis was performed for expression 
of IDO with GAPDH used as the loading control.  Densitometric analysis was performed using Scion Image and a 
ratio of GAPDH to IDO density was computed and presented.  Results are from one experiment representative of 
three performed.   
 
2.3.6 BMDC exposed to EtOH show reduced ability to prime allogeneic T cells in vivo and 
induce enhanced levels of IL-10 production 
Next, we examined the in vivo T cell priming abilities of control and EtOH-treated BMDC 
(bead-purified to >90% purity, as determined by CD11c staining) by performing adoptive s.c. 
injection of 5 x 105 B10 DC into naïve, allogeneic BALB/c recipients.  Six days later, the mice 
were killed, draining lymph nodes harvested and the total lymph node cells restimulated with 
donor alloantigen for 72h in MLR.  As shown in Figure 11A, EtOH-treated BMDC were 
significantly less efficient at priming naïve allogeneic T cells in vivo than control BMDC.  IL-10 
and IFNγ released into the culture supernatants were also measured at 72h.  Allogeneic T cells 
from both groups produced equivalent amounts of IFNγ, but T cells from animals given EtOH-
treated DC produced significantly higher levels of IL-10 in comparison to the control group 
(Figure 11B).  Thus, EtOH-treated BMDC were less efficient inducers of naïve allogeneic T cell 


























































































































Control EtOH  
Figure 11.  (A), T cell proliferative responses and (B), IL-10 and (C), IFNγ production in ex vivo MLR 
performed 6 days after s.c. injection of normal BALB/c recipients with bulk, bead-purified B10 CD11c+ DC, 
propagated with or without 50 mM EtOH for 8 days. 
Two x 105 T cells were cultured (1:1) with donor cells [bulk, irradiated (20 Gy) B10 splenocytes] for 72 h, as 
described in the Materials and Methods.  (A),  [3H]TdR was added for the final 16 h of culture.  Results show the 
ratio of proliferation in response to donor alloantigen to background proliferation of unstimulated LN T cells and are 
from one experiment representative of five performed.  (B), supernatants from the same 72h co-cultures were 
analyzed for IL-10 and IFNγ by ELISA.  Results are from four experiments.  *, p < 0.05; NS, not significant. 
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2.4 DISCUSSION 
In both humans and animal models, chronic EtOH consumption can adversely affect the immune 
system and its function (197, 192, 196, 193, 189, 256, 213, 295, 296).  With excessive EtOH 
ingestion, there are reduced T-cell proliferative responses, and impaired delayed–type 
hypersensitivity reactions (297-299, 261, 300), as well as an increased incidence of infectious 
diseases, including tuberculosis and hepatitis C viral infection (189-191).  Furthermore, 
prolonged EtOH exposure decreases the Ag-presenting capacity of human monocytes and 
monocyte-derived DC (222, 220).  However, the mechanisms underlying the immune-
compromised state of alcoholics have not been fully elucidated.  In this study, we have examined 
the influence of prolonged EtOH exposure on BM-derived mDC and pDC,. We show that 
prolonged EtOH exposure suppresses the cytokine-induced differentiation of mDC and pDC 
from normal BM precursors, with a more marked effect on pDC. EtOH also reduces the 
constitutive and CpG-induced expression of classic B7 costimulatory molecules, while sparing 
expression of the coregulatory molecule B7-H1 and reducing IL-12p70 production upon DC 
activation.  Consistent with these findings, EtOH impaired the stimulatory capacity of BMDC for 
naïve allogeneic T cells, both in vitro and in vivo, and enhanced the IL-10-producing capacity of 
in vivo-primed T cells.  Further, chronic EtOH consumption appears to have a more marked 
inhibitory effect on splenic compared to hepatic DC subsets, as assessed by their phenotypic and 
functional characteristics. 
The complex effects of EtOH on the immune system likely reflect many variables, 
including the duration (acute vs. chronic) and extent of exposure (EtOH concentration), as well 
as the influence of local or systemic factors, including cytokines or other immune-modulating 
agents.  Acute alcohol exposure inhibits the production of various cytokines (301, 227, 302, 219, 
221, 222, 234, 220, 236), while the generation of human monocyte-derived DC in ≥ 25 mM 
EtOH reduces the expression of the classic B7 family costimulatory molecules, CD80 and CD86 
(220). Our finding that EtOH exposure affects B7 family molecule expression on DC subsets 
differentially (reduced CD80/CD86, but unaffected B7-H1 expression) confirms and extends 
these observations.  The extent of the impact of EtOH exposure on expression of costimulatory 
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molecules in response to CpG may reflect the low constitutive level of expression of these 
molecules by BMDC.  Additionally, these effects of EtOH on the expression of key functional 
cell surface molecules could result from alterations in the cell membrane.  Thus, a change in 
membrane fluidity could affect the formation and stability of lipid rafts, known to contain 
membrane-associated proteins important in cell signaling.  Recent studies on macrophages 
support this view (234-236, 303).  Indeed, there is evidence that EtOH affects signal transduction 
pathways, such as the mitogen-activated protein kinase (MAPK) pathway in macrophages (234-
236).  Goral and Kovacs (236) showed recently that acute EtOH exposure inhibited activation of 
the MAPK pathway when murine macrophages were stimulated with a variety of TLR ligands.  
Collectively, these data indicate convincingly that EtOH negatively impacts the function of APC. 
DC are uniquely well-equipped APC, and their phenotype is important in defining the 
way that T cells are activated.  Szabo et al. (221, 222) have shown that EtOH inhibits both the 
differentiation and full maturation of human mDC, leading to decreased T cell stimulatory 
capacity. They ascribed this inhibition in part to reduced production of IL-12 (p40/p70) and 
concomitant, increased production of IL-10 by DC in response to LPS stimulation.  Similarly, in 
the present study, in vitro-generated murine BM-derived mDC and pDC exposed to EtOH 
showed inhibited differentiation, with a greater effect on pDC development, and reduced IL-
12p70 production in response to CpG stimulation.  A recent study of recombinant Hep G2 cells 
exposed to EtOH revealed that the cells were arrested in the G2/M phase, likely due, in part, to 
impaired Cdc2 activity (304).  We propose that in the presence of EtOH, replicating DC 
progenitors may be affected similarly, explaining the lower total numbers of DC recovered in 
culture.  pDC were affected more markedly, reflecting the poorer survival capacity of these cells 
in vitro compared with mDC (A.H. Lau and M. Abe, unpublished observations) and their greater 
sensitivity to potential toxins, such as dexamethasone (305). Alternatively, the cell development 
signaling pathways for pDC may be specifically affected by EtOH.  Hepatic and splenic DC 
subsets recovered from EtOH-fed, Flt3L-mobilized mice showed no significant reductions 
compared to Flt3L-treated controls.  The apparent discrepancy between the EtOH-mediated 
reduction in absolute DC numbers in response to Flt3L stimulation in vitro and in vivo may 
reflect differences in EtOH concentration and metabolism between the different test systems. 
EtOH-treated BMDC were poorer stimulators of allogeneic T cells in both in vitro assays 
and in vivo adoptive transfer experiments.  The reduced cell surface expression of CD80 and 
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CD86, associated with impaired T cell stimulatory capacity, is consistent with the influence of 
acute alcohol consumption on human monocyte and DC accessory cell function (221).  The 
importance of the CD80/86-CD28 costimulatory pathway in T cell activation is well-recognized 
(306-308).  Further, it has been documented that T cell anergy resulting from the lack of 
functional CD80/86-CD28 signaling can be overcome by the addition of exogenous IL-2.  In this 
study, we found that the expression of CD80 and CD86, as well as CD40, was reduced on EtOH-
treated BMmDC and BMpDC.  As expected, stimulation of T cells by these DC was reduced 
significantly. Addition of exogenous IL-2 did not overcome the anergic state (data not shown), 
suggesting that alternate mechanisms were responsible for impairment of T cell responsiveness.  
One possible mechanism whereby EtOH-treated DC may impair T cell responses is signaling via 
the CD274 (B7-H1)-PD-1 pathway, a recently-identified coregulatory pathway that inhibits T 
cell activation (309).  Unlike the classic costimulatory molecules (CD40, CD80, and CD86), B7-
H1 was not reduced significantly on EtOH-treated, CpG-stimulated mDC or pDC.  This finding 
may explain, in part, why the EtOH-treated DC were less stimulatory than control DC for naïve 
T cells.  The high B7-H1 to classical costimulatory molecule (B7-1 and B7-2) ratio that we 
observed suggests a role for this molecule in the inhibitory effect of EtOH-treated DC on T cell 
activation (Table 5).  Indeed, we have shown elsewhere (40) that blocking of B7-H1 expression 
on in vitro-generated murine DC enhances their T cell stimulatory ability.   
T cells primed in vivo with EtOH-exposed BMDC were found to produce more IL-10 
compared to T cells from control BMDC-injected mice, with no differences in IFNγ production.  
Further, IL-2 production in these cultures did not differ between the EtOH and control groups.  It 
has been shown that autocrine production of IL-10 can lead to T cell unresponsiveness (310).  
The increased production of IL-10, although not accompanied by changes in IFNγ production, 
may reflect skewing of T cells to produce more regulatory IL-10 rather than the Th1 cytokine, 
IFNγ.  Mandrekar et al. (220) showed that EtOH-treated human monocyte-derived DC exhibited 
reduced IL-12 and increased IL-10 production, that, when the DC were used as stimulators of 
naïve CD4+ T cells in vitro, led to reduced IFNγ production.  In our experiments, EtOH-treated 
BMDC were used to prime naïve T cells in vivo, which may account for the differences in 
cytokine production by T cells between the studies.  Further, in our adoptive transfer 
experiments, responses of CD8+ T cells were not excluded and may have contributed to IFNγ 
production.  The increased IL-10 production by T cells was not reproduced when naïve mice 
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were primed with hepatic or splenic DC from chronic EtOH-fed mice (Figure 22B).  IFNγ 
(Figure 22B) and IL-2 (data not shown) production by these T cells was also no different 
between EtOH and control groups.  This discrepancy between the influences of in vitro- and in 
vivo-derived DC may again result from inherent differences in EtOH concentration and 
metabolism between the different test systems. 
In summary, our studies show that the differentiation, phenotypic maturation and T cell 
stimulatory capacity of EtOH-treated BMDC subsets are impaired.  Prolonged exposure to EtOH 
inhibits BMDC maturation, characterized by reduced expression of surface costimulatory 
molecules; by contrast, expression of the coregulatory molecule CD274 (B7-H1) is unaffected.  
Interestingly, EtOH-exposed BMDC, while inducing less Ag-specific T cell proliferation, induce 
more IL-10 production.  Together, these data suggest that chronic EtOH exposure impairs the 
differentiation and functions of BMDC subsets, and may reflect one mechanism by which 
alcoholics have compromised immune function. 
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3.0  EFFECTS OF CHRONIC ETHANOL CONSUMPTION ON HEPATIC AND SPLENIC 
DENDRITIC CELL PHENOTYPE AND FUNCTION3 
3.1 INTRODUCTION 
As detailed in 2.1, there have been been limited studies investigating EtOH’s effects on the 
development and function of DC.  In Chapter 3, we examined the effects of prolonged EtOH 
exposure on the development and function of mDC and pDC from BM.  While these studies are 
important for determining the possible effects that EtOH may have on the in vivo differentiation 
and function of DC, there are inherent differences between in vitro-propagated DC and freshly-
isolated DC, especially when considering the environment in which DC reside or mature.  This 
functional difference between BMDC or liver or spleen DC has been shown with chemotaxis and 
migration experiments (119, 75).  Further, no studies to date have examined the effects of 
chronic EtOH administration on murine DC subsets, despite the availability of the mouse model 
for alcohol and immune function studies.  Thus, we sought to utilize the Meadows-Cook murine 
alcohol model (211, 212) to investigate effects of chronic EtOH on hepatic and splenic DC.  
The microenvironment in which DC develop or are activated can markedly influence 
their function and the outcome of their interactions with T cells. Within the liver, comparatively 
high levels of interleukin (IL)-10 and transforming growth factor (TGF)-β are produced by 
various liver cell populations (1).  These cytokines can confer tolerogenicity on DC by rendering 
the cells resistant to maturation and inhibiting their T cell stimulatory function (311). Indeed, 
liver DC have been implicated in liver transplant tolerance (137). Moreover, compared with 
splenic DC, murine hepatic DC are refractory to endotoxin stimulation, that appears to reflect 
comparatively low constitutive levels of TLR4 expression by liver DC (79). 
                                                 
3 Data and Text excerpted from (57). 
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Studies have consistently demonstrated an association between alcohol abuse and 
increased susceptibility to a variety of infectious diseases, including bacterial pneumonia and 
tuberculosis (Reviewed in 189).  Other studies have shown accelerated progression of chronic 
liver disease in patients with chronic HCV and alcohol use (190, 191).  As DC are important 
mediators of immune function, any inhibitory effects on their function may cause compromised 
immune function.  Of further clinical relevance, DC-based therapies are being investigated in 
several diseases, including hepatocellular carcinoma, in which chronic alcohol consumption is a 
major risk factor (312, 313).  Thus, evaluating the effects of prolonged EtOH exposure on the 
phentotype and function of in vivo-derived DC may provide insight into the compromised 
immune status of alcoholics.   
In the present study, we have assessed the influence of chronic EtOH administration on 
hepatic and splenic DC in vivo using a mouse model.  We have found that chronic EtOH 
administration in vivo exerts a greater inhibitory effect on splenic DC maturation and function 
(naïve T cell allostimulatory activity) than on maturation-resistant hepatic DC.  However, EtOH 
exposure increases the migratory capacity of hepatic DC in vivo compared to normal control 
hepatic or splenic DC.  Thus, chronic in vivo EtOH exposure exerts differential effects on 
hepatic and splenic DC. 
3.2 MATERIALS AND METHODS 
3.2.1 Animals 
Six- to eight-week old C57BL/10 (B10; H2Kb), C57BL/6 (B6; H2Kb), BALB/c (H2Kd), and 
C3H/HeJ (C3H; H2Kk) mice were purchased from The Jackson Laboratory and maintained in 
the specific pathogen-free Central Animal Facility of the University of Pittsburgh Medical 
Center.  Experiments were conducted under an Institutional Animal Care and Use Committee-
approved protocol.  The animals were fed a diet of Purina rodent chow and received tap water ad 
libitum unless specified.   
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3.2.2 In vivo EtOH administration 
B6 mice were separated randomly into control and EtOH-fed groups.  Mice in the EtOH group 
were given 10% w/v EtOH in tap water ad libitum for 2 days, 15% w/v EtOH for 5 days, then 
20% w/v EtOH for at least 8 weeks (212).  No adverse effects of this EtOH feeding protocol on 
behavior or weight gain compared with control mice were observed (3.3.2).  
3.2.3 Measurement of blood alcohol level 
Anti-coagulated blood was collected from mice using heparin and analyzed for blood alcohol 
levels using a commercial Alcohol Reagent Set kit (Pointe Scientific, Inc., Canton, MI) 
following the manufacturer’s recommended procedures.   
3.2.4 Serum alanine aminotransferase and aspartate aminotransferase levels 
Blood was collected without heparin and allowed to clot at room temperature for one hour.  
Blood samples were then centrifuged at 15000 x g at 4°C for 10 min.  Serum was collected and 
then analyzed by UPMC Presbyterian Shadyside Chemistry Labs for serum alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST).   
3.2.5 In vivo CpG administration 
Mice received CpG- B (100 µg in 0.1 ml) i.v. via the lateral tail vein, 12 to 16 h before liver and 
spleen DC isolation.   
3.2.6 Histological analysis of liver and spleen 
Liver and spleen tissues from control and EtOH-fed mice (8-10 weeks diet) were fixed with 
formalin then stained with hematoxylin and eosin to compare gross histology.   
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3.2.7 Immunofluoresence staining of tissue sections  
Blocks of liver and spleen were embedded in Tissue-Tek OCT (Miles Laboratories, Elkhart, IN), 
snap frozen in isopentane/liquid nitrogen, and stored at -80°C. Cryostat sections (8 µm) were 
fixed in 96% ethanol (10 min), blocked with 10% normal goat serum, and incubated overnight 
(4°C) with anti-CD11c biotin-mAbs (BD PharMingen). As a second step, slides were incubated 
with 1:3000 Cy2-streptavidin (Jackson Immunoresearch Lab, West Grove, PA), for 30 min at 
room temperature. Cell nuclei were stained with DAPI (4,6 diamidino-2-phenylindole; 
Molecular Probes, Eugene, OR). Slides were fixed in 2% paraformaldehyde, mounted in 
glycerol/PBS, and examined with a Zeiss Axiovert 135 microscope equipped with appropriate 
filters and a cooled CCD camera (Photometrics CH250, Tucson, AZ). Signals from different 
fluorochromes were acquired independently, and montages edited using the Adobe Photoshop 
software program (Adobe Systems, Mountain View, CA).  
3.2.8 Isolation and purification of liver and spleen DC 
DC were isolated from livers and spleens of animals given Flt3L [10 µg/day i.p. in phosphate 
buffered saline (PBS) for 10 consecutive days, as described (68, 79), with minor modifications].  
Briefly, a 22 gauge catheter was inserted in the inferior vena cava and blood collected for serum 
and measurement of blood EtOH levels.  Mice were perfused with 20 ml PBS, then livers and 
spleens removed.  Livers were disaggregated and digested for 30-45 min at 37°C in 10 ml type 
IV collagenase (1 mg/ml; Sigma-Aldrich, St. Louis, MO) supplemented with DNase (100 µg/ml; 
Roche, Nutley, NJ).  Liver non-parenchymal cells were isolated by density centrifugation (428 
mg/ml Histodenz; Sigma-Aldrich) at 1200 x g for 20 min at 4°C.  DC were enriched from bulk 
splenocytes by density centrifugation (160 mg/ml Histodenz) at 500 x g for 20 min at 20°C.  
Following centrifugation of liver or spleen cell suspensions, the interface cells were collected 
and washed twice in PBS.  CD11c+ cells were then purified using anti-mouse CD11c-coated 
immunomagnetic beads, as described above.   
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3.2.9 Antibodies for flow cytometry 
Monoclonal antibodies (mAbs) used for flow cytometry and cell sorting were those used in 
Chapter Three (2.2.2).  Additionally, rat anti-mouse PE-CCR7 (4B12; eBioscience), FITC-
conjugated or biotinylated-CD11a (LFA-1; 2D7), CD31 (PECAM-1; 390), CD54 (ICAM-1; 
1A29), CD62E (E-Selectin; 10E9.6), CD62L (L-Selectin; MEL-14), CD102 (ICAM-2; 3C4), and 
CD106 (VCAM-1; 429) (all from BD PharMingen).  
3.2.10 Media and reagents 
Media, Flt3L, TLR9 ligands (CpG) used were the same as in Chapter Three (2.2.2).   
3.2.11 Chemotactic agents 
Mouse recombinant CC chemokine CCL19/MIP-3β used in chemotaxis assay experiments was 
obtained from R & D Systems (Minneapolis, MN).  
3.2.12 Chemotaxis assay 
Assays were performed as described previously (121, 119) with minor modifications.  CD11c-
bead purified hepatic and splenic DC from control and EtOH-fed mice were stimulated for 16h 
with 2 µg/ml CpG-B.  Stimulated DC (2 x 105) were resuspended in 100 µl 0.5% BSA RPMI 
1640 (no FBS, without chemokine) in Transwells
® 
(5 µm pores; Costar, Cambridge, MA) which 
were placed in 24-well plates with 600 µl of chemokine dilution in 0.5% bovine serum albumin 
RPMI 1640 per well and incubated for 2 h at 37° C in 5% CO2 in air. After the incubation period, 
the Transwells®
 
were removed and migrated DC from the 24-well plates were collected and 
enumerated using a Coulter Counter (Beckman Coulter). For accurate comparison between 
experiments, results were expressed as the percentage of migrated DC.  Migration assays were 
performed in duplicate; experiments were repeated at least 3 times.  
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 3.2.13 Migration of DC in vivo 
Hepatic and splenic CD11c-bead purified DC were labeled cytoplasmically with the green 
fluorescent dye chloromethylfluorescein diacetate (CMFDA; Molecular Probes, Leiden, The 
Netherlands) (15 µM; 45 min at 37° C) or carboxyfluoroscein succinimidyl ester (CFSE; 
Molecular Probes) (5 µM; 15 min 37° C) according to the manufacturer’s instructions.  After two 
washes, 3-5x106
 
DC were injected s.c. into one hind footpad of allogeneic recipients (BALB/c).  
Popliteal DLN were removed 24 h after s.c. injection.  Inguinal LN were removed and served as 
negative controls.  LN cells were analyzed by FACS for the percentage of green fluorescent 
cells.  The number of DC migrating to DLN in vivo was determined by the following equation:  
(% green fluorescent cells in DLN x total number of cells recovered from DLN)/(number of DC 
injected s.c.).   
3.3 RESULTS 
3.3.1 Meadows-Cook Murine Model 
As discussed, the Meadows-Cook mouse model is one of three possible murine models of 
chronic ethanol administration that can be used.  This model was briefly assessed to ensure that 
mice had a similar phenotype to reported studies.   
3.3.1.1 Blood Alcohol Level 
The blood alcohol of mice was measured on the day that they were killed for experiments 
with blood being drawn 3-4 h after nocturnal cycle (ends at 6 am).  Consistent with published 
reports, the blood alcohol level (BAL) of mice varied, but was significantly elevated compared to 







































Figure 12.  Mice fed EtOH chronically have detectable BAL. 
B6 mice were fed EtOH for 8-24 w, as described in the Materials and Methods (3.2.2).  Age- and sex--matched 
control mice received water without EtOH.  BAL was quantified as described in Materials and Methods (3.2.3).  






3.3.1.2 Serum ALT and AST 
In alcoholic humans, elevated ALT and AST levels can be diagnostic for liver damage.  
However, in the Meadows-Cook murine model, it has been reported that there is no significant 
difference in AST or ALT between control and chronically EtOH-fed (8-24 w) mice (212).  
Consistent with these reports, there was no significant difference in serum AST or ALT between 

















Figure 13.  There is no difference in serum AST or ALT between control and EtOH-fed mice. 
B6 mice were fed EtOH for 8-24 w, as described in the Materials and Methods (3.2.2).  Age-matched control mice 
received water without EtOH.  Serum was collected and AST and ALT quantified as described in Materials and 








3.3.1.3 Histologic appearance of livers and spleens 
EtOH-fed mice displayed lipid accumulation in the liver compared to control mice in 
which livers appeared normal (Figure 14A).  However, no histologically detectable necrosis, 
increased inflammatory cells, or other morphologic changes were observed.  In contrast, the 
spleens of EtOH-fed mice showed no gross changes in histology compared to control spleens 
(Figure 14B).   
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Figure 14.  Histological appearance of livers (A) and spleens of (B) control and EtOH-fed mice. 
B6 mice were fed EtOH for 8 w, as described in the Materials and Methods (3.2.2).  Age-matched control mice 
received water without EtOH.  (A) Control liver sections show normal appearance, whereas the EtOH-fed liver 
sections show areas of lipid accumulation seen as areas of open space (lack of dye uptake) around hepatocyte nuclei 
(some representative areas indicated by arrowheads).  Top sections: Original magnification, 100x.  Bottom sections: 
Original magnification, 200x; (B)   Both control and EtOH-fed spleens exhibited normal gross histology by H & E 
staining.   Original magnification, 10x. 
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3.3.2 Flt3L treatment of control and EtOH-fed mice 
Flt3L has been commonly used in mice to increase the numbers of DC in both livers and spleens 
(314, 68).  However, there have been no reports of Flt3L use in the Meadows-Cook murine 
model of chronic alcohol intake.  Administration of Flt3L can cause changes in the organ weight 
to body weight ratio as a result of the increased DC and other hematopoietic cell numbers.  If 
prolonged EtOH administration negatively affected DC genesis, it would be expected that there 
would be a resulting decrease in the organ to body weight ratio, as there was no difference in 
body weight between the groups after chronic EtOH exposure (Figure 12A) (212).  However, 
there was no difference in the organ to body weight ratio for livers and spleens (Figure 15B), 


































































































Figure 15.  No changes in body weight (A) or organ weight (g)/body weight (kg) (B) between control and 
EtOH groups. 
B6 mice were fed EtOH for 8-24 w, as described in the Materials and Methods (3.2.2).  Age-matched control mice 
received water without EtOH.  (A) Mice were weighed before sacrifice; (B) Livers and spleens were weighed after 
removal and the data expressed relative to body weight.  Results are from (A) 14 or (B) 23-25 experiments and are 





 In fact, in vivo chronic EtOH consumption did not lead to significant reductions in 
absolute DC numbers recovered from Flt3L-mobilized mice (Figure 16).  Furthermore, the 
distribution of DC in the organs was unchanged, with liver DC residing predominantly around 
portal triads, but also appearing throughout the liver parenchyma, and splenic DC in the marginal 
zone and red pulp (Figure 17).  Thus, prolonged EtOH administration in mice did not affect DC 

























































Figure 16.  No difference in total number of DC recovered from EtOH-fed mice treated with Flt3L. 
B6 mice were fed EtOH for 8-24 w and age-matched control mice received water without EtOH, administered Flt3L 
and DC recovered from livers and spleens, as described in the Materials and Methods (3.2.2, 3.2.8).  Results are 
from six to seven experiments (representative of many) and are expressed as mean ± 1 SD  
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Figure 17.  Immunohistochemistry of liver and spleen sections reveals no apparent difference in numbers of 
DC and localization of DC with Flt3L administration in EtOH-fed mice. 
B6 mice were fed EtOH for 8 w, as described in the Materials and Methods (3.2.2).  Age-matched control mice 
received water without EtOH.  Liver and spleen sections were stained with biotinylated mAb anti-CD11c, 
followed by Cy2-streptavidin (green).  DAPI (blue) indicates nuclear staining.  200x magnification. 
3.3.3 Splenic DC subsets are more susceptible than hepatic DC subsets to in vivo 
modulatory effects of prolonged EtOH consumption on cosignaling molecule expression 
To assess the impact of prolonged EtOH exposure on DC subsets in vivo, we analyzed the 
maturation capacity of hepatic and splenic DC from mice fed EtOH for 8 weeks. DC were 
mobilized (with Flt3L) for the final 10 days before harvesting to obtain sufficient numbers of 
each DC subset for phenotypic and functional analysis.  Groups of mice were also given CpG-B 
(100 µg) i.v. for the final 16 h to determine the influence of chronic EtOH consumption on DC 
responsiveness to this activating agent in vivo.  Freshly-isolated hepatic and splenic DC were 
purified and analyzed by flow cytometry for the expression of costimulatory molecules (CD40, 
CD80, and CD86) as well as MHC class I and MHC class II (Figure 18, and unpublished 
results).  As reported previously (68, 79), administration of Flt3L alone did not affect cell surface 
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expression of these molecules (unpublished results).  Freshly-isolated splenic or hepatic mDC 
and pDC (especially) exhibited very low levels of surface costimulatory molecules.  Expression 
of CD86 was only slightly higher on liver DC subsets in response to in vivo CpG stimulation, 
whereas more marked upregulation of this molecule was observed on splenic DC (Figure 18).  
Expression of CD40 and CD80 followed the same pattern as CD86 (data not shown).  In mice 
fed EtOH, the inherently low intensity of CD86 expression on hepatic mDC and pDC differed 
only modestly in comparison to controls (Figure 18B, C).  However, the mean fluorescence 
intensity (MFI) for this molecule (and CD40 and CD80; data not shown) was lower on spleen 
DC from EtOH-treatment groups (Figure 18D, E).  MHC class II expression was also lower on 
CpG-stimulated splenic mDC and pDC from EtOH-fed mice, whereas this effect was not evident 
for hepatic DC subsets that expressed lower constitutive levels of MHC class II.   
The expression of CD274 (B7-H1) was also examined on hepatic and splenic DC from 
chronic EtOH-fed mice (Figure 18).  As with the costimulatory molecules, CD274 was expressed 
at very low levels on freshly-isolated hepatic DC, and was not impaired by long-term (8 w) 
EtOH administration.  Similarly, the higher level of CD274 on unstimulated and (especially) 
CpG-stimulated splenic DC was not reduced by long-term EtOH consumption.  Taken together, 
these results suggest that the T cell stimulatory function of splenic DC may be more susceptible 
than that of hepatic DC to the influence of long-term EtOH consumption.   
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Figure 18.  Freshly-isolated hepatic pDC (B) or mDC (C) exhibit little change in surface expression of MHC 
class II, the classic costimulatory molecule CD86, or the cosignaling molecule CD274/B7-H1/PD-L1 following 
chronic in vivo EtOH feeding, but splenic pDC (D) and mDC (E), that express constitutively higher levels on 
mDC, exhibit reduced expression of these molecules. 
B6 mice were fed EtOH for 8 w, as described in the Materials and Methods.  Age-matched control mice received 
water without EtOH.  Mice were treated with Flt3L (10 µg/day, i.p.) for 10 days, then received CpG (10 µg, i.v.) 16 
h prior to sacrifice.   Bulk, bead-purified CD11c+ hepatic and splenic DC were isolated, labeled with anti-CD11c 
(biotin-conjugated, revealed with SA-CyChrome) and anti-CD45R/B220 or anti-CD11b (FITC-conjugated) and 
either anti-IAb, -CD86, or –B7-H1 (PE-conjugated).  Cells were gated on CD11c+B220+ (pDC) or CD11c+CD11b+ 
(mDC) cells and expression of IAb, CD86, or B7-H1 analyzed.  Control DC are represented by the open black 
outline histogram and EtOH-fed mouse DC by the shaded histogram.  Background isotype control staining is shown 
in (A) and represented by the open black outline histogram.    Percent positive cells and MFI for each treatment 
group are indicated in the tables.  Results are from one experiment representative of three performed. 
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 3.3.4 Hepatic and splenic DC from EtOH-treated, control and CpG-stimulated mice are 
less efficient stimulators of naïve allogeneic T cell proliferation in vitro and in vivo 
Freshly-isolated resting and in vivo CpG-B-stimulated hepatic and splenic DC were next 
analyzed for their ability to stimulate naïve allogeneic T cells.  Consistent with the corresponding 
phenotypic data (Figure 18), splenic DC from mice fed EtOH for 8 w and stimulated in vivo with 
CpG-B were significantly less efficient inducers of naïve allogeneic T cell proliferation than 
control CpG-B-stimulated splenic DC (Figure 19).  Hepatic DC from control, CpG-B-stimulated 
mice were poorer stimulators than their splenic counterparts, whereas the stimulatory function of 
liver DC from CpG-B-stimulated, EtOH-fed mice was similar to that of spleen DC from the 






















































Figure 19.  T cell proliferative responses induced by hepatic or splenic DC isolated from EtOH-fed or control 
B6 mice, with or without CpG stimulation in vivo.   
Bulk, bead-purified CD11c+ hepatic and splenic DC were isolated from mice given EtOH or water alone for 8 w, 
Flt3L (10 µg/day, i.p.) for 10 days and CpG (100 µg, i.v.), 16 h prior to sacrifice.  Graded numbers of irradiated (20 
Gy) DC were co-cultured with 2x105 nylon wool-purified allogeneic C3H T cells for 72 h, as described in the 
Materials and Methods.  [3H]TdR was added for the final 16 h of culture.  Results are from one experiment 
representative of three performed and are expressed as means ± 1 SD.  *, p < 0.05 
 
 
The influence of EtOH treatment on the capacity of hepatic and splenic DC to produce 
IL-12p70, a potent inducer of T cell proliferation, in response to CpG stimulation was evaluated.  
Hepatic and splenic DC were bead-purified, stimulated overnight with CpG and culture 
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supernatants assessed for IL-12p70 production, as shown in Figure 20A.  Both EtOH-exposed 
hepatic and splenic DC produced significantly more IL-12p70 compared to control DC (Figure 
20A).  Interestingly, similar to BMpDC, production of IFNα in response to CpG-A stimulation 
was unaffected in both hepatic and splenic DC (Figure 20B).  It should be noted that bulk hepatic 





















































































Figure 20.  (A) IL-12p70 production by hepatic and splenic DC is increased with prolonged EtOH 
consumption but (B) IFN-α production is unaffected when DC are stimulated with CpG. 
Bulk, bead-purified CD11c+ hepatic and splenic DC were isolated from mice given EtOH or water alone for 8-10 w 
and Flt3L (10 µg/day, i.p.) for 10 days prior to sacrifice.  DC were stimulated for 16 h with (A) CpG-B (2 µg/ml) or  
(B) CpG-A (2 µg/mL) and supernatants collected for measurement of (A) IL-12 and (B) IFNα production by 
ELISA.  Results are from three experiments and are expressed as means ± 1 SD.  *, p < 0.05. 
 
We measured IDO protein levels by western blot and found that EtOH-treated, 
unstimulated or CpG-stimulated spleen DC and liver DC (50 mM) exhibited unimpaired IDO 
production (Figure 21).  Thus, this enzyme is unlikely to play a role in the observed impaired T 
















































































































1.51.4GAPDH:IDO 1.41.5 1.61.5 1.61.6
 
Figure 21.  IDO production by hepatic or splenic DC is unchanged by EtOH exposure in vitro or in vivo, 
respectively.   
Bulk, bead-purified CD11c+ hepatic and splenic DC were isolated from mice given EtOH or water alone for 8 w, 
Flt3L (10 µg/day, i.p.) for 10 days and CpG (100 µg, i.v.), 16 h prior to sacrifice.  Western blot analysis was 
performed for expression of IDO with GAPDH used as the loading control.  Densitometric analysis was performed 
using Scion Image and a ratio of GAPDH to IDO density was computed and presented.  Results are from one 
experiment representative of three performed.   
 
3.3.5 Hepatic, EtOH-exposed DC show increased ability while splenic, EtOH-exposed DC 
show reduced ability to prime allogeneic T cells in vivo compared to control DC 
Next, we examined the in vivo T cell priming abilities of control and EtOH-treated hepatic and 
splenic DC (bead-purified to >90% purity, as determined by CD11c staining) by performing 
adoptive s.c. injection of 5 x 105 B10 DC into naïve, allogeneic BALB/c recipients.  Six days 
later, the mice were killed, draining lymph nodes harvested and the total lymph node cells 
restimulated with donor alloantigen for 72h in MLR.  As shown in Figure 22A, EtOH-exposed 
hepatic DC were significantly more efficient at priming naïve allogeneic T cells in vivo than 
control hepatic DC.  In contrast, EtOH-exposed splenic DC were significantly less efficient at 
priming naïve allogeneic T cells compared to control splenic DC (Figure 22A).  IL-10 and IFNγ 
released into the culture supernatants were also measured at 72h.  Allogeneic T cells from both 
groups produced equivalent amounts of both IL-10 and IFNγ (Figure 22B).  Thus, EtOH-treated 
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hepatic and splenic DC are differentially affected by EtOH-exposure on their capacity to induce 
















































































































































































































Figure 22.  (A), T cell proliferative responses and (B), IL-10 and (C), IFNγ production in ex vivo MLR 
performed 6 days after s.c. injection of normal BALB/c recipients with bulk, bead-purified B6 hepatic or 
splenic CD11c+ DC from control or EtOH-fed mice. 
Two x 105 T cells were cultured (1:1) with donor cells [bulk, irradiated (20 Gy) B6 splenocytes] for 72 h, as 
described in the Materials and Methods.  (A), [3H]TdR was added for the final 16 h of culture.  Results show the 
ratio of proliferation in response to donor alloantigen to background proliferation of unstimulated LN T cells and are 
from one experiment representative of five performed.  (B), supernatants from 72h co-cultures were analyzed for IL-
10 and IFNγ by ELISA.  Results are from four experiments.  *, p < 0.05; NS, not significant. 
3.3.6 Migration of hepatic and splenic, control and EtOH-exposed DC 
3.3.6.1 In vitro migration of CpG-B-stimulated, hepatic and splenic, control and EtOH-
exposed DC to MIP3β 
Altered chemotactic responses by DC can affect their migration to secondary lymphoid 
tissue, and subsequently the manner by which T cells are activated.  Thus, hepatic and splenic 
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DC were evaluated for the effects of prolonged EtOH exposure on the ability of cells to migrate 
to CCL19/MIP-3β, a ligand of CCR7, in vitro.   
Previous reports from our lab that show that immature, freshly-isolated, hepatic (75) and 
splenic (119) DC do not migrate in vitro, precluding the need for in vitro chemotaxis assays to be 
run for immature DC.  Thus, hepatic and splenic DC from control and EtOH-fed mice were 
matured overnight with CpG-B and then evaluated for their migratory capacity to CCL19 (Figure 
23).  Previous data from our group have shown that a concentration of 0.94 ng/mL CCL19 is 
sensitive for detecting differences in migration, while concentrations of 94 µg/mL CCL19 and 
higher are on the plateau or generate maximal migration responses (119).  Thus, two 
concentrations of CCL19 were assessed - 0.94 ng/mL (Figure 23) and 0.94 µg/mL (as a control 
to show dose response, data not shown).  2 x 105 DC were placed in Transwell®
 
 chambers over 
these two concentrations of CCL19 and after 2 h incubation, the number of DC that migrated 
from the Transwell® chamber were enumerated.  Interestingly, at the lower concentration of 
CC19, both hepatic and splenic DC from EtOH-fed mice exhibited significantly inhibited 
migratory response to the chemokine compared to control hepatic and splenic DC (Figure 23).  
In fact, neither the hepatic nor splenic EtOH-exposed DC displayed chemotaxis to CCL19 (≥ 
10% migration over control with no chemokine).  However, at 0.94 µg/mL CCL19, this 















Liver Control Liver EtOH Spleen Control Spleen EtOH
3.71 ± 1.85 3.11 ± 1.12 4.39 ± 1.28 4.58 ± 1.03
















Figure 23.  In vitro chemotaxis of hepatic and splenic, control and EtOH-exposed DC to CCL19. 
B6 mice were fed EtOH for 8-24 w, as described in the Materials and Methods.  Age-matched control mice received 
water without EtOH.  Mice were treated with Flt3L (10 µg/day, i.p.) for 10 days then DC from livers or spleens 
isolated as described in Materials and Methods then stimulated for 16h with CpG-B (2 µg/mL).   DC were placed in 
the upper wells of Transwell®
 
chambers over CCL19.  Positive chemotaxis was considered ≥10% migration over 
control without chemokines.  Bar charts and data table below show % migration to CCL19 expressed as means ± 1 
SD.  Results are from three experiments; each chemokine dilution was tested in duplicate.  *, p<0.05.   
3.3.6.2 Phenotypic analysis of adhesion molecule and CCR7 expression on freshly-isolated 
and CpG-B-stimulated, hepatic and splenic, control and EtOH-exposed DC 
Hepatic and splenic DC were also evaluated for the effects of prolonged EtOH exposure 
on the expression of various adhesion molecules.  Changes in adhesion molecule expression can 
affect DC migration and subsequently, the ability of DC to prime naïve T cells.  Freshly-isolated, 
immature, hepatic and splenic DC were purified and analyzed by flow cytometry for the 
expression of surface adhesion molecules (CD11a, CD11b, CD31, CD54, CD62E, CD62L, 
CD102, and CD106) as well as CCR7 (Figure 24).  Freshly-isolated hepatic or splenic DC 
exhibited low to moderate levels of CD31, CD54, CD62E, CD62L, CD102, and CD106, as 
expected (Figure 24).  Although expression of CD11b (hepatic control only), CD31 (hepatic 
control and EtOH-exposed), CD54 (splenic EtOH-exposed only), and CD62E (splenic control 
and EtOH-exposed) were increased with CpG-stimulation (all p < 0.05), levels of these adhesion 
molecules remained low to moderate (Figure 24).  Only one adhesion molecule, CD106, was 
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significantly reduced (p < 0.05) upon CpG-stimulation and this was for both control and EtOH-
exposed splenic DC.   
CD11a was highly expressed on both hepatic and splenic DC that was reduced (not 
significantly) upon CpG-B stimulation.  With CpG-stimulated, hepatic DC, EtOH exposure 
resulted in significantly higher expression of CD11a compared to control, hepatic DC (Figure 
24).  Expression of CCR7 was low on freshly-isolated, immature hepatic and splenic DC, and 
increased significantly with CpG stimulation (p<0.005) (Figure 24).  However, EtOH-exposure 
did not affect CCR7 expression.  Although there was no difference in the expression of CCR7 on 
hepatic or splenic DC, as determined by FACS, surface expression was not necessarily reflective 
of the functional status of receptors.  These results suggest that EtOH has limited effects on 
adhesion molecule expression.  In contrast to coregulatory molecules (Figure 18), the effects of 
EtOH exposure appear to affect CD11a expression on hepatic DC significantly with no 












Control 1250.2 ± 800.1 45.5 ± 9.0 30.8 ± 2.2 121.7 ± 37.8 165.5 ± 78.1 64.4 ± 31.4 175.6 ± 95.6 189.7 ± 81.1 57.7 ± 11.2
EtOH 1621.1 ± 361.7 57.1 ± 18.8 30.6 ± 3.9 119.7 ± 28.6 129.7 ± 43.4 59.7 ± 19.3 222.9 ± 99.3 187.1 ± 92.0 61.6 ± 10.9
Control + CpG 976.1 ± 188.1 62.3 ± 18.6 46.5 ± 2.0 177.4 ± 77.0 302.7 ± 110.3 89.9 ± 39.0 175.4 ± 92.5 137.7 ± 14.7 629.2 ± 168.0
EtOH + CpG 1314.7 ± 253.2 66.0 ± 20.2 47.7 ± 2.3 166.8 ± 92.5 311.8 ± 140.8 91.8 ± 51.7 184.6 ± 135.2 157.1 ± 35.6 659.8 ± 253.4



















Control 1590.1 ± 503.3 71.5 ± 34.5 40.4 ± 11.7 151.9 ± 49.2 148.9 ± 66.8 87.7 ± 42.6 173.5 ± 40.1 298.7 ± 124.0 46.5 ± 1.3
EtOH 1591.9 ± 914.2  77.1 ± 28.2 42.0 ± 7.6 130.6 ± 36.1 149.5 ± 59.3 79.6 ± 29.2 173.6 ± 45.6 311.1 ± 144.4 45.1 ± 3.0
Control + CpG 859.6 ± 306.0 73.1 ± 23.5 48.9 ± 2.0 179.2 ± 76.9 245.4 ± 103.9 115.9 ± 46.3 184.5 ± 92.7 184.6 ± 84.5 563.1 ± 133.0
EtOH + CpG 983.2 ± 188.5 77.0 ± 20.7 71.1 ± 44.9 182.6 ± 49.8 252.8 ± 120.8 103.6 ± 31.1 170.6 ± 75.5 169.5 ± 78.4 459.3 ± 166.8





















Figure 24.  (A) Hepatic or (B) splenic DC show no differences in expression of various adhesion molecules or 
CCR7 when freshly isolated or after CpG stimulation, except for EtOH-exposed, CpG-B-stimulated liver DC 
(A) that express more CD11a. 
B6 mice were fed EtOH for 8-24 w, as described in the Materials and Methods.  Age-matched control mice received 
water without EtOH.  Mice were treated with Flt3L (10 µg/day, i.p.) for 10 days, then DC from livers or spleens 
isolated as described in Materials and Methods.  Freshly-isolated DC were either analyzed by FACS or stimulated 
for 16h with CpG-B (2 µg/mL) for 16 h then analyzed by FACS analysis.   DC were labeled with anti-CD11c 
(FITC- or PE-conjugated) and either anti-CD11a, -CD11b, -CD31, -CD54, CD62E, -CD62L, -CD102, -CD106  
(biotin-conjugated and revealed with streptavidin-FITC or FITC-conjugated) or –CCR7 (PE-conjugated).  Cells 
were gated on CD11c+ cells and expression of adhesion molecules or CCR7 analyzed.  Bar charts show MFI for the 
molecules indicated and are expressed as mean ± 1 SD.  The table below shows means ± 1 SD.  Results are from 
four-nine experiments.  *, p<0.05; **, p<0.005.  In the table below, bolded text is p <0.05.  
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3.3.6.3 In vivo migration of freshly-isolated (immature) and CpG-B-stimulated (mature), 
hepatic and splenic, control and EtOH-exposed DC 
Given the results showing the ability of freshly-isolated, immature, control and EtOH-
exposed, hepatic and splenic DC to prime naïve T cells in vivo (Figure 22) as well as the CD11a 
and CCR7 cell surface expression data (Figure 24), we first examined the migration of these 
immature hepatic and splenic DC to DLN after s.c. injection by rare-event, flow cytometric 
analysis.  Our group has reported previously (68) that allogeneic mature, liver-derived CD8α+ 
DC; mature, splenic CD8α+ DC, and immature and mature splenic CD8α- DC (119) migrate to 
the DLN of recipients within 24 h of sc injection.  Liver and spleen DC from control and EtOH-
fed mice were freshly-isolated, labeled with CFSE, then injected s.c. into the hind footpads of 
allogeneic BALB/c mice.  18-24 h later, popliteal DLN were removed, and total LN cells 
analyzed rare-event, flow cytometric analysis for percent positive green fluorescent cells.  
Interestingly, significantly more hepatic DC from EtOH-fed mice migrated to DLN compared to 
control hepatic DC (Figure 25A).  However, these data correlate with adoptive transfer data that 
shows that hepatic DC from EtOH-exposed mice have increased capacity to induce naïve T cell 
proliferation in vivo (Figure 22A).  If hepatic, EtOH-exposed DC have a greater capacity to 
migrate to DLN, it may explain the increased T cell activation seen with these DC.  In contrast, 
splenic control or EtOH-exposed DC showed no difference in migration (Figure 25A).  Thus, in 
the case of splenic DC, the reduced capacity of splenic, EtOH-exposed DC to induce naïve T cell 
proliferation compared to control DC (Figure 22A) likely results from the immature phenotypic 
status of splenic, EtOH-exposed DC (Figure 18D, E), as seen in in vitro MLR (Figure 19), rather 
than increased DC numbers reaching T cell areas in the secondary lymphoid tissue.  
Next, we examined the in vivo migration of CpG-matured hepatic and splenic DC from 
control and EtOH-exposed mice to DLN.  Freshly-isolated DC from livers and spleens were 
stimulated with CpG for 16-18 h, labeled with CFSE, then injected and analyzed 24 h later as 
described above.  Again, as with immature DC, significantly more hepatic DC from EtOH-
exposed mice migrated to DLN compared to control hepatic DC (Figure 25B).  It should be 
noted that with maturation, more hepatic DC, control and EtOH-exposed, migrated to DLN 
compared to immature DC (Figure 25), likely due to upregulated CCR7 on mature DC (Figure 
24A).  Both immature and CpG-matured splenic DC from control and EtOH-exposed mice 
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showed no difference in migration.  In concord with the adhesion molecule expression data 
(Figure 24), EtOH exposure appears to significantly affect the in vivo migratory capacity of 














































Liver Control Liver EtOH Spleen Control Spleen EtOH
A
B p < 0.05
p < 0.05
 
Figure 25.  In vivo migration of (A) immature or (B) mature hepatic or splenic DC from control or EtOH-fed 
mice. 
Rare-event FACS analysis was performed on LN cells from DLN isolated 18-24 h after s.c. injection of normal 
BALB/c recipients with 3-5 x 106  bulk, bead-purified, CFSE-labeled B6 CD11c+ DC, isolated from livers or spleens 
from control or EtOH-fed mice.  (A) Immature, freshly-isolated DC; or (B) CpG-stimulated (16 h) DC were 
analyzed by rare event, FACS analysis for the percentage of green fluorescent cells.  The number of DC migrating to 
DLN in vivo was determined by the following equation:  (% green fluorescent cells in DLN x Total number of cells 
recovered from DLN)/(Number of DC injected s.c.)  Results are from three to six experiments.  *, p < 0.05. 
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3.4 DISCUSSION 
In both humans and animal models, chronic EtOH consumption can adversely affect the immune 
system and its function (315, 189, 256).  With excessive EtOH ingestion, there are reduced T-
cell proliferative responses, and impaired delayed–type hypersensitivity reactions (297-299, 261, 
300), as well as an increased incidence of infectious diseases, including tuberculosis and 
hepatitis C viral infection (189-191).  Furthermore, prolonged EtOH exposure decreases the Ag-
presenting capacity of human monocytes and monocyte-derived DC (222, 220).  However, the 
mechanisms underlying the immune-compromised state of alcoholics have not been fully 
elucidated.  In this study, we have utilized an established murine chronic alcohol consumption 
model, the Meadows-Cook model, to examine the effects of chronic EtOH administration on the 
phenotype and function of hepatic and splenic DC.  Prolonged EtOH consumption appears to 
exert a more marked inhibitory effect on splenic compared to hepatic DC subsets, as assessed by 
their phenotypic and functional characteristics.  However, hepatic DC from EtOH-fed mice 
appear to have increased migratory capacity in vivo, concomitant with their increased CD11a 
surface expression compared to control hepatic DC.   
As discussed in Chapter 1 (1.3) and Chapter 2 (2.4), EtOH exerts complex effects on the 
immune system that are likely reflect many variables, including the duration (acute vs. chronic) 
and extent of exposure (EtOH concentration), as well as the influence of local or systemic 
factors, including cytokines or other immune-modulating agents.  Szabo et al. (221, 222) have 
shown that EtOH inhibits the differentiation and full maturation of human mDC, leading to 
decreased T cell stimulatory capacity.  In Chapter 2, we report in vitro-generated murine BM-
derived mDC and pDC exposed to EtOH show inhibited differentiation, with a greater effect on 
pDC, compared to mDC, development (Figure 4).  Hepatic and splenic DC subsets recovered 
from EtOH-fed, Flt3L-mobilized mice showed no significant reductions in DC numbers 
compared to Flt3L-treated controls (Figure 16).  The apparent discrepancy between the EtOH-
mediated reduction in absolute DC numbers in response to Flt3L stimulation in vitro and in vivo 
may reflect differences in EtOH concentration and metabolism between the different test 
systems. 
Currently, there are no reports that define the influence of long-term in vivo EtOH 
administration on DC phenotype and function.  Cook et al. (213) have updated a murine model 
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of chronic EtOH consumption (211) and examined splenic T cells.  They found that T cells were 
more activated, both in phenotype and function, similar to what is found in human chronic 
alcoholics.  The same group also reported (281) that splenic CD11b+ cells recovered from EtOH-
fed mice and cultured overnight (a procedure that enhances DC maturation) appeared to be 
activated, as defined by increased CD80 and CD86 expression.  In the present study, we found 
that freshly-isolated, resting hepatic DC and splenic DC exhibited different phenotypes (liver DC 
were more immature) and that EtOH consumption reduced splenic DC costimulatory molecule 
expression, while hepatic DC (that constitutively express lower levels of these molecules) were 
not noticeably affected.  The inhibitory effect of chronic EtOH consumption on splenic DC 
maturation in response to CpG stimulation was confirmed by in vitro MLR assays and by 
analysis of host T cell responses following adoptive transfer of EtOH-exposed DC.  These data 
are consistent with those previous reports concerning chronic EtOH consumption and splenic 
macrophage function.  Whereas in the present study we examined the expression of 
costimulatory molecules on splenic DC activated in vivo, Cook et al. (281) cultured splenic 
CD11b+ cells overnight, in the absence of EtOH, to stimulate upregulation of costimulatory 
molecules.  Conceivably, the manner by which the APC were stimulated may affect the 
upregulation of costimulatory molecules.   
Hepatic DC have been shown to be refractory to stimulation with LPS or pro-
inflammatory cytokines (144, 79).  This inherent, comparative unresponsiveness may have 
evolved in response to a need for tolerance to orally-derived Ag and microbial products that are 
delivered continuously from the gut (1). The comparative inability of liver DC to elicit strong T 
cell responses may contribute to the persistence of hepatic viral infections and to cancer in the 
liver (both primary and metastatic) as well as to the tolerogenicity of liver allografts.  Further, 
recent studies of murine liver DC (70, 71) have indicated a higher relative proportion of pDC 
(versus mDC) in comparison to the spleen.  As pDC are being widely investigated for their role 
in innate and adaptive immunity (282, 27, 39), as well as in immune regulation and tolerance 
(35, 282), their comparative prominence in the liver may have a significant impact on 
immunological events within the liver microenvironment.  CpG-activated liver DC were not 
affected significantly in regards to phenotypic maturation and in vitro T cell stimulatory capacity 
by prolonged EtOH consumption, and we hypothesize that the unique cytokine 
microenvironment of the liver, the liver’s ability to metabolize EtOH, as well as the comparative 
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resistance of liver DC to maturation, may partially spare these cells from the inhibitory effects of 
prolonged EtOH exposure.   
However, in apparent contrast to the phenotypic maturation and in vitro T cell 
stimulatory capacity data, when naïve mice were primed with hepatic DC from chronic EtOH-
fed mice, these DC were found to have greater Ag-specific T cell proliferation compared to 
control hepatic DC (Figure 22A).  Evaluation of DC migration to DLN showed that hepatic DC 
from chronic EtOH-fed mice migrated in greater numbers compared to control (Figure 25A).  
Further, when surface expression of various adhesion molecules were evaluated on DC, CD11a 
was found to be more highly expressed on EtOH-exposed hepatic DC compared to control 
(Figure 24A).  These data are in agreement with a study that showed that LFA-1 was increased 
on Jurkat T cells when exposed to acute low concentrations of EtOH and with enhanced 
adhesion between these EtOH-exposed Jurkat cells and their target cells (Raji cells), even in the 
absence of specific Ag (316).  It can be speculated that the higher expression of CD11a, 
important for leukocyte adhesion to endothelial cells and thus, subsequently, extravasation, on 
EtOH-exposed hepatic DC may contribute to its greater migration to secondary lymphoid tissue. 
It should be noted, however, that although these in vivo migration studies show increased 
migration of hepatic DC from EtOH-fed mice, this model of migration is just that – a model.  
These data may not mimic what actually happens to hepatic DC in vivo in their normal 
environment.  In the liver there are many other factors present, including, but not limited to, the 
cytokine microenvironment.  The increased CD11a in the context of the liver may actually 
prevent hepatic DC from migrating out of the liver, even when stimulated by TLR9 in vivo.  In 
fact, it has been shown in both mouse and rat studies of chronic EtOH administration that surface 
expression of CD54 (ICAM-1), the ligand for CD11a/CD18 (LFA-1), is significantly increased 
on hepatocytes of EtOH-fed animals compared to pair-fed controls (267, 317).  Further, when a 
blocking Ab to CD18 was added to in vitro cultures of polymorphonuclear neutrophils (PMN) 
and hepatocytes from EtOH-fed rats, AST release was reduced significantly compared to 
cultures that did not receive the Ab (267).  When the blocking Ab was used in chronic EtOH-fed 
rats in vivo, serum AST levels were significantly reduced compared to rats receiving control Ig 
Ab (267).  Bautista (267) suggests that these observations support the hypothesis that adhesion 
molecules, in this case CD18 and CD54, are involved in chronic alcohol-induced hepatic injury 
(increased AST) by enhancing the interaction between leukocytes and hepatocytes.  Further, in 
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vitro data show that hepatic DC from EtOH-fed mice have significantly reduced migration to 
CCL19 compared to control hepatic DC (Figure 23).  It can be speculated that reduced 
chemotaxis to CCR7 ligands, combined with increased CD54 on hepatocytes and increased 
LFA-1 on DC, may all contribute to reduced migration of hepatic DC from the liver in chronic 
EtOH drinkers.  This may be one mechanism by which alcoholics are particularly susceptible to 
infections and viral hepatitis since the ability of the DC to reach draining secondary lymphoid 
tissue and present Ag to T cells may be impaired. 
When splenic DC from control and EtOH-fed mice were used to prime naïve mice, 
splenic DC from EtOH-fed mice were found to induce reduced Ag-specific T cell proliferation 
compared to controls (Figure 22A), similar to findings with EtOH-exposed BMDC (Figure 11A).  
However, the increased IL-10 production by T cells primed in vivo with EtOH-exposed BMDC 
(Figure 11B) was not reproduced when splenic DC from chronic EtOH-fed mice were used 
(Figure 22B).  IFNγ production by these T cells was also no different between EtOH and control 
groups.  Migration of splenic DC in vivo was also analyzed and showed no difference between 
control and EtOH-exposed groups (Figure 25).  Thus, the reduced ability of splenic DC from 
EtOH-fed mice to prime naïve T cells in vivo is likely a result of the reduced costimulatory 
molecule expression and subsequent inhibited stimulatory capacity.  The discrepancy between 
the influences of in vitro- and in vivo-derived DC on T cell priming may result from inherent 
differences in DC phenotype and function, as well as EtOH concentration and metabolism 
between the different test systems. 
 In summary, our studies show that the long-term, in vivo EtOH administration exerts 
differential effects on liver versus spleen DC subsets.  Hepatic DC, that are inherently immature, 
weakly immunogenic and comparatively resistant to maturation, appear resistant to the inhibitory 
effects of EtOH on functional maturation and T cell stimulatory capacity.  However, the in vivo 
migratory capacity of hepatic DC from EtOH-fed mice is concomitantly increased with 
expression of CD11a, in comparison to control hepatic DC.  In contrast, secondary lymphoid 
organ (spleen) DC from mice chronically fed EtOH exhibit impaired functional maturation and 
function in response to CpG stimulation, with no overall changes in migration or adhesion 
molecule expression.  Together, these data suggest that altered maturation, function, and 
migration of hepatic and splenic DC, resulting from prolonged EtOH exposure, may be involved 
in the compromised immune function of alcoholics. 
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4.0   IMMUNE REACTIVITY IN CHRONIC ETHANOL-CONSUMING MICE 
4.1 INTRODUCTION 
As discussed in the Introduction (1.3.1), the Lieber-DeCarli (or equivalent) and Meadows-Cook 
murine models of chronic EtOH consumption, while similar in certain aspects, such as observed 
pathological changes, have also been shown to exhibit differences, such as mortality rate and 
overall stress induction.  There have been limited studies to date using the Meadows-Cook 
murine model of chronic EtOH consumption.   
There is clinical evidence that chronic EtOH consumption compromises normal host 
defenses by impairing or altering immune responses (189, 318, 256).  Cell-mediated and humoral 
immunity have been examined in chronic alcoholics.  In alcoholic patients, delayed-type 
hypersensitivity (DTH) responses are impaired (319, 320, 297) and serum Ig (particularly IgG 
and IgA) levels elevated (321).  In mice fed the LD diet for 10-11 days, impaired DTH has been 
reported (299, 261).  Further, in ovalbumin (OVA) T cell receptor (TcR) transgenic (Tg) mice 
specific for I-Ad-restricted 323-339 OVA peptide (MHC class II restricted; OT-II), it was shown 
that EtOH significantly inhibited Ag-specific DTH responses (216).     
As discussed in 1.3.3, it is theorized that there is Th1/Th2 skewing towards a decrease in 
Th1 and increase in Th2 responses with chronic EtOH administration.  However, the data 
currently reported are still inconclusive.  Further work must be done to fully elucidate the effects 
of chronic EtOH consumption on cell-mediated immunity.  Whereas T cell-dependent responses 
appear to be inhibited by chronic EtOH feeding (299, 261), other functional effects, i.e. Th1/Th2 
skewing, have yet to be determined. 
The study of B cell responses and the effects of chronic EtOH has been difficult.  
Although chronic alcoholics appear to exhibit impaired B cell function, as evidenced by 
increased circulating serum Ig (321), studies in this patient population have shown that they have 
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intact T cell-independent antibody (Ab) response to pneumococcal polysaccharide vaccination 
(322).  In vitro studies show different results from those seen in alcoholics, with inhibited Ab 
production by B cells (323).  In the mouse model, it has been shown that alcohol either enhances 
or does not alter Ab production (262).  Thus, the seemingly conflicting data indicate complex 
effects of chronic EtOH exposure on B cell functions.   
 A few studies have examined the effects of chronic EtOH consumption on, presumably, 
the function of CD8 T cells.  It has been hypothesized (324) that chronic EtOH sensitizes the 
liver, by an unknown mechanism, such that activated CD8+ T cells migrating to the liver induce 
hepatic injury rather than dying by apoptosis, as they normally do (325).  Jerrells’ group has 
utilized murine models of Listeria monocytogenes and murine cytomegalovirus (MCMV) 
infection, which can induce liver damage but that can be controlled/cleared in normal mice 
(324), to study the effects of EtOH consumption on CD8+ T cell function (326, 327).  Control of 
infection to both pathogens requires CD8+ T cells (328, 329).  When mice were infected with L. 
monocytogenes, those that consumed EtOH were more susceptible to infection and had greater 
hepatic injury (326).  Further, if immune mice (control mice that had cleared a previous 
infection) were then fed an EtOH diet and then reinfected, these animals were unable to control 
the growth of the bacteria (326).  Simlarly, when mice were infected with a sub-lethal dose of 
MCMV to induce hepatitis, EtOH-fed animals were unable to clear the viral infection, unlike the 
self-limiting hepatitis infection in control mice (327).  While neither study has shown definitely 
that CD8+ T cells mediate the impaired immune responses to either infection, the important role 
of CD8+ T cells in the clearance of both pathogens suggests an impairing effect of EtOH on 
CD8+ T cells is likely to be involved at least to some extent.     
No reports to date have investigated cell-mediated and humoral responses in the 
Meadows-Cook model of chronic EtOH consumption.  In chapters 3 and 4, we have examined 
the effects of chronic EtOH exposure on DC function.  In this chapter, we evaluate cell-mediated 
and humoral responses in the Meadows-Cook murine model by examining Ag-specific direct cell 
killing, CD4 and CD8 T cell responses and serum Ig production.   
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4.2 MATERIALS AND METHODS 
  
4.2.1 In vivo EtOH administration 
B6 mice were separated randomly into control and EtOH-fed groups and fed an EtOH diet as 
described in Chapter Three (3.2.1, 3.2.2) except that mice were maintained on EtOH for 12-24 
weeks (212).  No adverse effects of this EtOH feeding protocol on behavior or weight gain 
compared with control mice were observed.  
4.2.2 Immunization of mice with OVA 
As described previously (330), Biomag beads (iron oxide; Polysciences, Inc., Warrington, PA) 
were covalently linked to OVA protein (Sigma-Aldrich) (OVA-Fe) according to the 
manufacturer’s instructions.  Naive control and EtOH-fed mice were immunized with OVA-Fe or 
PBS by bilateral footpad (25 µg) and haunch (75 µg) s.c. injections on day 0 and boosted in the 
same manner at day 7.  In vivo killing assays were run on day 11.   
4.2.3 In vivo killing assay 
In vivo Ag-specific lytic activity was measured by an in vivo killing assay, as previously 
described (331, 6, 332). Briefly, mouse splenocytes were collected and pulsed with SIINFEKL 
(250 ng/ml; Sigma Chemical Co.) and labeled using a high concentration of CFSE (5 µM; 
CFSEhigh). Mouse splenocytes without SIINFEKL peptide were labeled using a low 
concentration of CFSE (0.5 µM; CFSElow) as an internal control. Ten x 106 cells of each 
population were mixed and injected into mice i.v. via the lateral tail vein. The relative quantity of 
CFSEhigh and CFSElow cells in DLN (popliteal and inguinal) was determined by flow cytometry 5 
h after injection.  Specific lysis was calculated according to the following formula: {1-[(ratio of 
CFSElow/CFSEhigh of naive mouse)]/[(ratio of CFSElow/CFSEhigh of vaccinated mouse)] X 100. 
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4.2.4 Enzyme-linked immunosorbent spot (ELISPOT) 
Spleens from control and OVA-Fe immunized mice were collected at the same time as DLN.  
CD4+ and CD8+ T cells were enriched by incubation with anti-mouse-CD4- or anti-mouse-CD8-
coated immunomagnetic beads (10 µl/107 cells; Miltenyi Biotec) for 15 min at 4°C, then 
positively selected by passage through a MACS column (Miltenyi Biotec), yielding a highly-
enriched (>90%) CD4+ and CD8+ T cell population to use as responders in ELISPOT. 
Splenic APC (depleted of Thy1.2+ and CD4+ cells) from naive C57BL/6 mice were 
loaded with OVA (1 mg/mL), SIINFEKL (10 µg/ml), or no Ag for 4 h, washed three times in 
PBS, and used as target cells for 48-h IFN-γ or IL-5 ELISPOT assays (both plates and Ab sets 
from BD PharMingen).  For the ELISPOT assay, 4 x 104 APC per well and 2 x 105 of either 
CD4+ or CD8+ T cells (responders) per well were suspended in 200 µL of AIM V® medium 
(Invitrogen Corp., Carlsbad, CA).  OVA-loaded APC were used with CD4+ T cells and 
SIINFEKL-loaded APC were used with CD8+ T cells.  APC with no Ag loaded were used as 
negative controls for both CD4+ and CD8+ T cells.  ELISPOT plates were incubated at 37°C for 
the indicated time and developed as described in the manufacturer's protocols. 
4.2.5 Serum Ig Analysis by ELISA 
Serum was collected from each mouse as described in 3.2.4 and analysed by ELISA for Ab titre.  
Ninety-six-well EIA/RIA [Corning Incorporated Life Sciences (Costar), Acton, MA] flat-bottom 
plates were coated with 50 µl/well of 100 µg/ml OVA protein in 0.1 M NaHCO3 and incubated 
overnight at 4°C.  Plates were washed twice in PBS supplemented with 0.05% Tween 20 (PBS-
Tween), then blocked with 1% bovine serum albumin (w/v) in PBS at room temperature for 2 h.  
Plates were washed two times with PBS-Tween, then 100 µl of serially diluted serum samples, 
diluted in PBS supplemented with 10% (v/v) fetal bovine serum (FBS/PBS), were added to the 
plates.  Serial dilutions of reference serum samples of known titer were also assayed on each 
plate.  After samples and reference serum were added, plates were incubated overnight at 4°C.  
The plates were washed four times with PBS-Tween, and 100 µl of either biotinylated goat anti-
mouse IgG1 mAb (0.4 µg/mL; Caltag Laboratories, Burlingame, CA) or rat anti-mouse IgG2a 
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mAb (1 µg/ml; BD PharMingen) in FBS/PBS was added to each well and incubated at room 
temperature for 45 min.  Plates were washed five times with PBS-Tween, and 100 µl/well of 
avidin-conjugated horseradish peroxidase (BD PharMingen) at 1:1000 in FBS/PBS was added to 
each plate and incubated at room temperature for 30 min. The plates were washed a final five 
times with PBS-Tween, and 100 µl of substrate, 3,3′,5,5′-Tetramethylbenzidine (TMB) 
Substrate (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) added to each well.  
Reactions were terminated by addition of 100 µl of TMB Stop solution (Kirkegaard & Perry 
Laboratories, Inc.) was added to each well.  Color development was assessed at 405 nm.  Titers 
of OVA-specific IgG1 and IgG2a were determined by calculating the dilution required to 
achieve an optical density reading of 0.2, and were expressed as the reciprocal of that dilution. 
4.3 RESULTS 
4.3.1 In vivo analysis of Ag-specific lytic activity between control and EtOH-fed mice 
The function of CD8+ T cells are of great importance in various diseases to which chronic 
alcoholics appear to be more susceptible, such as viral hepatitis and malignancy.  Thus, we 
compared the in vivo Ag-specific killing capacity in control and chronic EtOH-fed mice.  Ag-
specific lytic activity was measured in vivo by targeted lysis of Ag-loaded APC in the periphery 
(Figure 26).  Quantification of Ag-specific lysis of target cells demonstrated very similar lytic 































Figure 26.  Control and chronic-EtOH fed mice exhibit equivalent in vivo Ag-specific lytic activity. 
B6 mice were fed EtOH for 12-24 w, as described in the Materials and Methods.  Age-matched control mice 
received water without EtOH.  Mice were immunized with either OVA-Fe or PBS at day 0, boosted at day 7, then 
injected i.v. with CFSE-labeled, Ag-specific target cells on day 11.  5 h later, popliteal and inguinal LN were 
removed and assayed by FACS analysis for quantification of Ag-loaded (CFSEhigh) and control (No Ag, CFSElow) 
target cells.  (A),  Representative histograms of control, PBS (No OVA) immunized group which shows no 
difference in lysis of SIINFEKL-loaded target cells (CFSEhigh) compared to control target cells (CFSElow).  In 
contrast, control-fed or EtOH-fed mice immunized with OVA-Fe display lysis of Ag-loaded target cells (CFSEhigh) 
compared to control target cells(CFSElow). Results are from one experiment representative of nine experiments.  (B),  
Average % Ag-specific killing of target cells for control, pair-fed mice and EtOH-fed mice.   Results are mean ± 1 
SD from nine experiments. 
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4.3.2 Ag-specfic cytokine production by CD4+ and CD8+ T cells from control and EtOH-
fed mice 
As discussed above, it has been speculated that chronic EtOH-fed mice exhibit Th1/Th2 
skewing.  We examined these mice for potential Th1/Th2 polarization by examining Ag-specific 
cytokine production of IFNγ and IL-5 by ELISPOT and ELISA.  CD4+ and CD8+ splenic T cells 
from the immunized mice were used as responders to Ag-loaded APC in ELISPOT (Figure 27).  
T cells (CD4+ and CD8+) from control and EtOH-fed mice produced equal amounts of IFNγ in 
an Ag-specific manner (Figure 27).  IL-5 production was extremely low in both groups; in fact, 
the quantity was too low to quantify (data not shown).  Analysis of IFNγ production by ELISA 
showed that cytokine production was also very low, as expected, considering the ELISPOT data 
(data not shown).  IL-5 production was not detectable by ELISA, also in agreement with 
ELISPOT data (data not shown).  The ELISPOT assay itself was working, as positive control 
wells, containing T cells stimulated with phytohemagglutinin (PHA), in both IFNγ and IL-5 
plates had too many positive cells to count.  The lack of difference in IFNγ production between 
control and EtOH-fed groups indicates a lack of Th1/Th2 skewing in mice fed EtOH for 12-24 
weeks. 
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Figure 27.  Ag-specific CD4+ and CD8+ T cells from control and EtOH-fed mice produce equivalent amounts 
of IFNγ. 
B6 mice were fed EtOH for 12-24 w, as described in the Materials and Methods.  Age-matched control mice 
received water without EtOH.  Mice were immunized with either OVA-Fe or PBS at day 0, boosted at day 7, then 
tested for in vivo Ag-specific lytic activity on day 11.  When mice were killed for DLN for the in vivo killing assay, 
spleens were removed and CD4+ and CD8+ T cells isolated by magnetic bead isolation as described in the Materials 
and Methods.  Isolated CD4+ and CD8+ T cells were used as responders to Ag-loaded APC in ELISPOT.   Results 




4.3.3 Serum IgG1 and IgG2a production is equivalent between control and EtOH-fed mice 
After two immunizations with OVA-Fe, we observed no difference in humoral immune 
responses by chronic EtOH consumption (Figure 28).  In general, there was considerable mouse 
to mouse variation in both the control and EtOH-fed groups, with many mice having little to no 






































Figure 28.  Serum levels of IgG1 and IgG2a are equivalent in control and EtOH-fed mice. 
B6 mice were fed EtOH for 12-24 w, as described in the Materials and Methods.  Age-matched control mice 
received water without EtOH.  Mice were immunized with either OVA-Fe or PBS at day 0, boosted at day 7, then 
tested for in vivo Ag-specific lytic activity on day 11.  When mice were killed for DLN for the in vivo killing assay, 
blood was collected without heparin, allowed to clot, then serum collected.  Serum was analyzed by ELISA for IgG1 
and IgG2a levels.  Horizontal bars indicate mean values.  Results are from seven to nine experiments. 
4.4 DISCUSSION 
As discussed in the Introduction, murine models of chronic EtOH consumption, while in many 
ways able to mimic the human condition, still exhibit differences.  To date, there has been no 
published report detailing the effects of chronic EtOH consumption on cell-mediated or humoral 
immunity using the Meadows-Cook model.  Studying these effects may provide insight as to the 
possible immunologic defects that these mice exhibit and, subsequently, the usefulness of this 
murine model in the study of various immune cells, cell function impairments (i.e. cytokine 
production by T cells), and viral or bacterial disease models.  It should be noted that ultimately, 
we are examining a murine model which is limited by the length of EtOH exposure, number of 
immunizations, the animal system (mice do not get cirrhosis), as well as use of a model Ag 
(OVA) that may not appropriately reflect impaired immune responses in EtOH-fed mice.  
The data presented are from mice which have been fed EtOH for 12-24 weeks.  The in 
vivo killing assay shows that there is no difference in Ag-specific lytic activity between control 
and EtOH-fed mice (Figure 26).  In these studies, we used naïve C57BL/6 mice immunized at 
day 0 and boosted at day 7.  It is possible that the length of EtOH-exposure may need to be 
lengthened in order to see any defects in lytic activity.  Furthermore, the killing that was 
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quantified in Figure 26 could be from either NK cells or CD8+ T cells.  The possibilities exist 
that neither cell population is affected in the Meadows-Cook model, or that one population is 
compensating for the other population, which is impaired.  Considering the existing data on 
EtOH’s effects on NK and CD8+ T cells (326, 247-250, 327, 251), it seems possible that NK 
cells are impaired by chronic EtOH consumption but that CD8+ T cell activation is enhanced.  In 
order to specifically test the impact of NK cell or CD8+ T cell populations, NK cell deficient 
mice or OT-II Tg mice would be fed EtOH and Ag-specific lytic activity tested in these mice.   
We also found no difference in IFNγ production and a lack of significant IL-5 production 
between control and EtOH-fed groups (Figure 27).  These data suggest no Th1/Th2 polarization 
in EtOH-fed mice, which is supported by equivalent Ag-specific serum IgG1 and IgG2a levels 
between control and EtOH-fed mice (Figure 28).  At a recent meeting of the Alcohol and 
Immunology Research Interest Group (Maywood, IL, 2005), it was reported that, in mice 
immunized with TNP-KLH and adjuvant, CpG for Th1 skewing and alum for Th2 skewing, there 
was no change in Th2 IgM, IgG1, or IgE in mice with up to 32 weeks of EtOH consumption on 
the Meadows-Cook model (333).  Th1 responses, as measured by IgG2a and IgG2b production, 
were decreased in EtOH-fed animals, but only in mice with 32 weeks of EtOH consumption.  
Overall, it appears that, with >32 weeks EtOH consumption, Th1 responses fail but Th2 
responses remain intact.  Thus, humoral responses appear to be resistant to the effects of EtOH in 
the Meadows-Cook model, requiring >32 weeks of EtOH consumption before impairments 
appear.   
Thus, the Meadows-Cook model shows impaired DC function and possible impairments 
in T cells, B cells, and NK cells.  Further evaluation of this model will require mice being fed 
EtOH for extended periods of time, as well as the possible use of Tg mice, to better evaluate the 
impact of EtOH on specific cell populations.  Overall, it appears that this model will contribute 
to the evaluation of chronic EtOH consumption on various immune cells and function. 
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5.0  SUMMARY AND CONCLUDING DISCUSSION 
Chronic alcoholics are known to be more susceptible to various diseases, including those caused 
by bacterial and viral pathogen, such as tuberculosis and viral hepatitis, as well as malignancies 
(91, 245, 189-191, 246).  Various immune cell populations have been evaluated in the past for 
impairment in function due to EtOH exposure, but the few studies to date have studied the 
effects of EtOH on DC, the most important APC of the immune system.  Further, these studies 
are limited to human peripheral blood monocyte-derived myeloid DC.  With the availability of a 
mouse model of chronic EtOH consumption (Meadows-Cook model) as well as hematopoietic 
agents which allow the generation of enough DC to study, the effects of chronic EtOH 
consumption on DC development and function can now be assessed.  Further, by better 
understanding the cell-mediated and humoral responses in this model, it will be possible to study 
DC (and other cells, i.e. other leukocytes or endothlelial cells) in the context of various models 
of infection or disease. 
 We have determined, herein, that prolonged EtOH exposure affects the development and 
function of mDC and pDC derived from BM precursors.  Both mDC and pDC development were 
inhibited by EtOH exposure during their generation in vitro in a dose-dependent manner, with 
pDC being more susceptible to EtOH’s effects than mDC (Figure 1).  Further, the function of 
EtOH-treated mDC and pDC, when stimulated with HSV or TLR9 ligand CpG, was inhibited 
compared to control DC, as determined by phenotypic maturation markers (Figure 6) as well as 
reduced capacity to stimulate naïve allo-T cell proliferation (Figure 8).  More interestingly, when 
control and EtOH-exposed BMDC were adoptively transferred, EtOH-exposed DC were poorer 
at priming naïve T cells in vivo (Figure 11A).  Further, EtOH-exposed DC primed T cells that 
produced more IL-10 when restimulated with alloAg ex vivo (Figure 11B).  The reduced 
allostimulatory capacity of EtOH-exposed DC is probably due to their immature phenotype and 
perhaps also because of their higher CD274/B7-H1 expression (Figure 7).  To test if CD274 
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plays a role in the reduced proliferation of EtOH-exposed BMDC, a blocking Ab to CD274 
could be used on the DC in similar in vitro and in vivo experiments.  By using a blocking Ab, 
one could determine the level of involvement of this coregulatory molecule on the impaired 
function of EtOH-exposed BMDC.   
The effects of chronic EtOH exposure on DC freshly-isolated from mice were also 
assessed.  Liver and spleen DC were differentially affected by EtOH exposure, with EtOH 
seeming to exert a more marked inhibitory effect on spleen DC, as determined by phenotypic 
(Figure 18) and functional characteristics (Figure 19).  Both liver and spleen DC, when freshly-
isolated, are immature in phenotype (Figure 18).  Thus, they are both poor at stimulating naïve T 
cell proliferation in comparison to mature DC (Figure 19).  Interestingly, although classic 
phenotypic maturation markers, such as CD40, CD80, and CD86, were all expressed at low 
levels on both control and EtOH-exposed, freshly-isolated DC, EtOH-exposed liver and spleen 
DC were both significantly poorer stimulators of naïve allo-T cells in MLR compared to control 
freshly-isolated liver and spleen DC.  These data suggest that there is another mechanism by 
which EtOH-exposure affects the allostimulatory capacity of immature liver and spleen DC.  It is 
possible that a marker (other coregulatory molecules) not yet tested and/or altered DC cytokine 
production are involved in the inhibitory function of EtOH-exposed DC.  By determining what 
genes or proteins are affected in liver and spleen DC, such as by microarray, it may be possible 
to narrow the search for molecules involved in the inhibitory function of EtOH-exposed 
immature liver and spleen DC. 
When liver and spleen DC were stimulated with TLR9 ligand CpG, spleen DC from 
EtOH-fed mice were inhibited in phenotypic maturation (Figure 18) as well as function (Figure 
19) while hepatic DC, which are inherently more resistant to maturation, showed no such 
inhibitions in response to EtOH exposure (Figure 18 and 18).  It is likely that the unique 
tolerogenic environment of the liver makes resident DC resistant to the effects of EtOH.  It is 
possible that if the liver is exposed to an even more extended diet of EtOH (>12 weeks), liver 
DC may subsequently lose their resistance to the inhibitory effects of EtOH, perhaps due to 
altered function in other hepatic cells (i.e. KC, LSEC, hepatocytes).   
Interestingly, when immature hepatic and splenic DC were tested for their in vivo 
capacity to prime naïve allo-T cells, hepatic DC from EtOH-exposed mice had increased ability 
to prime naïve allo-T cells compared to control hepatic DC (Figure 22A).  In contrast, splenic 
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EtOH-exposed DC had reduced capacity to prime naïve allo-T cells compared to control splenic 
DC (Figure 22A).  The reduced priming ability of EtOH-exposed splenic DC compared to 
control splenic DC corresponded with in vitro phenotypic maturation and functional data (Figure 
18 and 18).  However, the increased priming ability of EtOH-exposed hepatic DC compared to 
control hepatic DC did not correspond with, in fact, seemed to conflict with phenotypic and in 
vitro functional data (Figure 18 and 18).  We then hypothesized that EtOH-exposure might affect 
the capacity of hepatic (and possibly splenic) DC to migrate to secondary lymphoid tissue.  
Examination of both immature and mature DC migration to draining lymph nodes in vivo 
revealed greater migration of EtOH-exposed hepatic DC compared to control hepatic DC and no 
differences between splenic DC groups (Figure 25).  More, adhesion molecule expression data 
suggest that EtOH-exposure affects expression of CD11a, which is highly expressed on liver DC 
and is significantly higher in expression on CpG-stimulated, EtOH-exposed hepatic DC (Figure 
24A).  Altered expression of this adhesion molecule may affect hepatic DC migration which has 
been shown to be affected by EtOH exposure in vitro and in vivo.  Use of a blocking Ab to 
CD11a on DC would provide insight into its importance in increased hepatic DC migration with 
EtOH exposure.  Similarly, as in vitro migration of hepatic and splenic DC in response to a 
CCR7 ligand is affected by EtOH exposure (Figure 23), it would be useful to investigate the role 
of CCR7 on migration.  By desensitizing the receptor (by pre-incubation with a CCR7 ligand 
such as CCL19), we can investigate the importance of CCR7 on DC migration.  Further, 
combining CD11a blockade and CCR7 desensitization in migration experiments would reveal 
any possible synergistic effects between the adhesion molecule and CCR7 pathways.   
Cell-mediated and humoral immune responses of mice fed EtOH on the Meadows-Cook 
model for 12-24 weeks reveals no differences in comparison to control pair-fed mice (Figure 26-
27).  A variety of factors could contribute to the apparent absence of effect of chronic alcohol 
consumption on systemic immune reactivity.  As recently presented at the AIRIG 2005 meeting 
(333), the length of EtOH administration may affect different immune cells at different rates.  
While we have shown differential deficits in hepatic and splenic DC function from mice 
consuming EtOH for 8-10 weeks, Waldschmidt et al. (333) showed that it was necessary that 
mice were kept on the diet at least 32 weeks before seeing deficits in humoral immune responses.  
Another variable may be length of immunization.  It is possible that the mice may have needed 
more immunizations with Ag to show responses or may have needed an adjuvant in order to 
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generate a strong enough response to detect.  In the same study by Waldschmidt et al. (333), 
mice were immunized with Ag and either a Th1 or Th2 adjuvant to promote humoral responses.  
Further, the timing of immunizations may be important.  In our study, we immunized at day 0 
and boosted at day 7 then examined sera at day 11.  It may be possible that the timings of boosts 
and sera collection may need to be modified.  Waldschmidt et al. (333) boosted at day 21 and 
collected sera at day 28.  Thus, many variables may contribute to optimizing the detection of 
impairments in cell-mediated and humoral immune responses. 
The studies discussed herein have provided insight into the field of chronic EtOH 
exposure and its effects on DC development, phenotypic maturation, and function.  These studies 
can provide a foundation for further studies to investigate the effects of chronic EtOH exposure 
on immune function and disease processes within a mouse model. 
One disease model that could be used to further our work would be to study the effects of 
EtOH on DC function in the clearance of Listeria monocytogenes, a common infectious 
bacterium that is normally cleared in a healthy individual.  We have shown that DC exposed to 
chronic EtOH treatment are impaired in their responses to stimulation via TLR9, which 
recognizes bacterial DNA.  It has also been shown by Jerrells et al. (326) that chronic EtOH 
consumption by mice prevents their ability to clear infection.  By studying DC in mice fed 
chronic EtOH and infected with L. monocytogenes, further insight could be gained into the role 
of (TLR9 function in) DC in the immune compromised state of chronic alcoholics.   
Viral infection is another disease process which is increased in chronic alcoholics.  A 
disease model that could be used to study the effects of EtOH on DC function in the clearance of 
viral infection would be murine cytomegalovirus (MCMV), a cytopathic β-herpesvirus.  In 
humans, CMV infection of immunosuppressed individuals (i.e. transplant patients, AIDS) is a 
leading opportunistic infection that can manifest in various clinical symptoms or pathologies, 
including hepatitis, pneumonitis, and colitis (334).  In mice, MCMV causes acute, self-limiting 
hepatitis depending on both host (i.e. cytokine production) and viral factors (327), with control 
of viral infection dependent upon CD8+ T cells with contribution from NK cells and CD4+ T 
cells (335).  Importantly, it was recently shown that MyD88 and TLR9 are critically required in 
the rapid antiviral response (reductions in cytokine production) (336).  For DC, MyD88 was 
required for the upregulation of CD86 expression in response to MCMV (336).  It has been 
reported previously that chronic EtOH in mice infected with MCMV prevents the clearance of 
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disease (327).  In vivo evaluation of EtOH’s inhibitory effects on DC (when triggered through 
TLR9) can be evaluated in the context of a disease state by using this murine viral infection 
model, which requires TLR9 involvement for the clearance of viral infection.   
An alternative murine model of hepatitis caused by viral infection uses lymphocytic 
choriomeningitis virus (LCMV).  The inoculation of adult immunocompetent mice with the 
Armstrong strain of LCMV leads to a well-characterized acute systemic infection, with the virus 
replicating in many tissues, including the liver and spleen.  LCMV-specific CD8+ CTL responses 
play a key role in the control of infection within 7-10 days (337).   Recently, Belz et al. (338) 
showed that CD8α+ DC are principal in presenting Ag to CD8+ T cells, thus initiating CTL 
responses.  Further, Montoya et al. (339) show that initially, CD8α+ DC and mDC are rapidly 
activated early in LCMV but by day 3 post-infection, the number of pDC, which are type-1 IFN 
producers, recruited to the spleen was drastically increased.  By using type-1 IFN-receptor 
knockout mice, they show that type-1 IFNs enhance the activation and apoptosis of mDC and 
CD8α+ DC during early infection, however, type-1 independent pathways for maturation of DC 
during LCMV infection exist (339).  By studying the kinetics of DC activation and recruitment 
to the spleen, such as Montoya et al. (339), we could determine if there is a deficiency in a DC 
population, either in numbers or function.  Our studies of pDC development from BM precursors 
seemed to show selective developmental inhibition of this subset.  It is possible that this same 
inhibition occurs in the mouse model and that lack of appropriate numbers of pDC to respond to 
LCMV infection prevents control of infection.  Further, EtOH-induced impairments in migration 
of DC to the spleen or functional defects in ability of DC to initiate appropriate T cell responses 
may potentially be involved in EtOH’s inhibitory effects, and ultimately prevent clearance of 
LCMV. 
Other health consequences of chronic alcohol intake and the immune system could also 
be examined.  For example, it has been well documented that alcohol intake can affect the 
healing of burn and trauma injury (340), with increased infectious complications.  Langerhans 
cells (LC) or dermal DC could be affected by EtOH and subsequently affect their immune 
function.  Initial studies by Schlueter’s group have shown that loss of LC occur within 8 weeks 
of chronic EtOH feeding and becomes more pronounced with prolonged length of EtOH 
exposure (341).  Further, they found that the migration of DC out of the skin to draining LN was 
delayed in EtOH-fed mice compared to control mice, although the overall magnitude of LC 
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migration was equivalent (341).  While defective migration of LC may contribute to the immune 
compromised state in burn and trauma injuries of chronic alcoholics, impaired LC function (i.e. 
stimulatory capacity or ability to cross-prime) may also be contribute.  Thus, it would be worth 
investigating the effects of chronic EtOH exposure on the function of other cell types, such as the 
LC.   
Our investigations of EtOH’s effects on DC development and function are the first in the 
mouse model and the first to analyze EtOH’s effects on liver and spleen DC.  The consequences 
of EtOH exposure on DC in the clinical setting are extensive.  Not only are these effects 
important in host defense and immune response, but also in the combined effects that EtOH may 
have when used concurrently with other drugs, such as immunosuppressive agents (i.e. 
Rapamycin, Cyclosporin A, corticosteroids, mycophenolate mofetil).  Further, by utilizing our 
current knowledge of EtOH’s effects on DC and by studying the direct effects of chronic EtOH 
consumption in bacterial and viral infection models, it may be possible to gain further insight 
into the immune compromised status of alcoholics, especially in the context of liver viral 
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